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1 
PREFACE 
Since before I even started studying psychology, schizophrenia and psychotic 
disorders were among my primary field of interest. When I landed my dream position 
as a psychologist at the inpatient unit of child and adolescent psychiatry in Aalborg, 
my interest was further sparked in the meetings with young patients and their families.  
I was and am interested in the patients and how they are affected by the disorder: the 
special sense of reality, their social relations and cognition, the long-term outcome 
and how they find their way, living with schizophrenia and perhaps recovering from 
it. Parents and patients often asked me what the future would look like and I was not 
always sure what to tell them.  
The research unit of child and adolescent psychiatry in Aalborg is fairly young – it 
was established in 2008 by Professor Hans-Christoph Steinhausen. A journal club was 
established and as clinicians, we were invited to join research projects. With my 
interest in schizophrenia, I signed up to work on a review of the outcome of early-
onset schizophrenia in the winter of 2009/10. Early in the stages of our collaboration, 
Hans-Christoph Steinhausen suggested that I should broaden the scope and do a full 
PhD study on the subject. Once the protocol was accepted at the university, my PhD 
journey began in December 2010.  
During my time as a PhD student, I have held a joint position of part-time clinical 
work and part-time research. Owing to this combination, a job change - into a position 
as team leader in an outpatient clinic for young adults with schizophrenia - and the 
birth of my third child, the PhD has taken 6 years and 8 months. It has been a long 
and sometimes hard journey and I have been looking forward to the finish line. Never 
once, though, have I regretted going in to research – it has given me many wonderful 
experiences, collaborators, friends and newfound knowledge.  
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3 
PROGRESSION OF THE PROJECT AND 
STUDY AIMS 
The overarching theme of the PhD study is the outcomes of early-onset schizophrenia 
(EOS).  
I started out by accumulating knowledge on the outcome of EOS into a systematic 
review (study 11) in order to obtain optimal knowledge for studying the disorder in 
the nationwide Danish registers. Next, psychiatric records from patients diagnosed 
with schizophrenia in childhood or adolescence were collected from all child and 
adolescent psychiatric departments in Denmark in order to investigate the validity and 
accuracy of diagnoses in the Danish Psychiatric Central Research Register (DPCRR)2 
(study 2). The last part of my project consisted of a register study (study 3) and 
investigated the outcomes of EOS compared to adult-onset schizophrenia (AOS) in 
terms of both psychiatric outcome (inpatient days, hospitalizations, comorbid 
substance use and involuntary admissions) as well as outcomes related to functioning 
(educational level, primary source of income and institutionalization). 
 
The thesis aims to answer the following research questions: 
a) What do we currently know about the outcome of EOS and does it differ 
from adult-onset?  
 
b) What is the validity of schizophrenia diagnoses from child and adolescent 
psychiatric departments in Denmark and how is the accuracy between a 
schizophrenia diagnosis in the DPCRR and the diagnosis written in the 
psychiatric record?  
 
c) Based on Danish register-based data, are there differences between EOS and 
AOS in the following:  
 
- Number of inpatient days in short- and long-term outcome 
- Premorbid characteristics 
- Psychiatric outcome and measures of functioning 
 
 
 
 
4 
CONCEPTS AND DEFINITIONS 
The definitions of EOS and very-early-onset schizophrenia (VEOS) varies 3-6. In the 
current studies, EOS is defined as onset prior to 18 years of age and VEOS as onset 
prior to 13 years of age, which is in line with most studies1. AOS refers to adult-onset 
schizophrenia. Another term for early-onset is adolescent-onset, which is usually 
defined as onset between 13-17 years of age, where early-onset does not have a lower 
cut-off range. VEOS and childhood-onset schizophrenia (COS) are often used 
interchangeably with a tendency for VEOS to be the European term and COS used 
more in US studies. Prepubertal schizophrenia or pediatric schizophrenia are rarely 
used in contemporary research. In order to avoid terminology confusion, VEOS will 
be used consistently for studies regarding VEOS or COS throughout the thesis, with 
the exception of the large-scale COS study from the National Institute of Mental 
Health (NIMH), which is commonly referred to as the NIMH-COS cohort/sample7.  
EOS is used for early-onset schizophrenia (including childhood onset), VEOS for 
childhood-onset, EOP is used for early-onset psychosis, and AOP for adult-onset 
psychosis. FEP is used for first-episode psychosis.  
 
OUTLINE OF THE THESIS 
Chapter 1 is a general introduction to the field of EOS and the main areas of the thesis.  
Chapter 2 describes the methods used in the three studies with regards to sample 
selection, methods, main focus and choice of statistical models.  
Chapter 3 describes the results from the three studies. 
Chapter 4 consists of a discussion of the studies and findings, strengths and 
limitations.  
Chapter 5 is a perspective on which implications for the field and future research 
studies, we might draw from the thesis.  
Chapter 6 is an epilogue on my thoughts on what to tell future patients and parents 
asking me about prognosis and outcome. 
Chapter 7 is a conclusion with short, take-home messages in answers to the research 
questions outlined earlier.  
English and Danish summary of the findings are available at the end of the thesis.  
 
5 
CHAPTER 1: INTRODUCTION  
EARLY-ONSET SCHIZOPHRENIA IN A HISTORICAL CONTEXT 
Psychotic disorders and madness have been described in children and adolescents as 
early as the 1800s 8. Going back through historical archives, psychotic disorders are 
believed to have existed through the history of mankind with possible descriptions 
going back as far as Pharaonic Egypt, in the second millennium before Christ. The 
first clinical and academic descriptions of the disorder have been attributed to Emil 
Kraepelin, who, in 1887, described the disorder ‘dementia praecox’ in his 
classification of mental disorders, and also believed some children with mental 
handicaps to be suffering from this. Kraepelin regarded schizophrenia as a brain 
disease and understood it as a form of early dementia of the mind and a poor prognosis 
was an underlying principle9. Eugen Bleuler later coined the term ‘schizophrenia’ and 
‘the group of schizophrenias’ in a lecture given in 1908 and opposed the notion put 
forth by Kraepelin that schizophrenia was necessarily a neuro-degenerative disease9.  
Some of the early descriptions of childhood schizophrenia resemble current 
knowledge; as early as 1926 August Homburger described that childhood 
schizophrenia was characterized by negativism, withdrawn, unpredictable and strange 
behavior10. He described three different types of premorbid features: children with 
normal development and IQ; children with premorbid mental retardation; and children 
with IQ in the normal range but character anomalies and strange behavior10. Onset 
could either be acute and catatonic or slow and hebephrenic with cognitive 
deterioration10. Jakob Lutz described childhood schizophrenia as separate from adult 
schizophrenia in the 1930s and a decade later, Leo Kanner and Hans Asperger outlined 
two types of autism from the group of childhood psychoses10. Kanner and Elwyn 
James Anthony later proposed three groups of psychoses with and without a 
relationship to schizophrenia: early infantile autism, childhood schizophrenia and 
disintegrative psychoses of childhood, the latter referring to psychoses related to brain 
damage and childhood dementia. These classifications later came to influence the 
International Classification of Diseases – Classification of Mental and Behaviorural 
Disorders (ICD) in ICD-9, and the Diagnostic and Statistical Manual of Mental 
Disorders (DSM) in DSM-III and DSM-III-R 10. Lauretta Bender was interested in the 
clinical presentation of childhood psychoses and started her work in the 1940s at 
Bellevue Hospital in New York8. In 1958, she described schizophrenia in children as 
distinct from ‘the pseudo-defective group’, which resembled children with infantile 
autism; from ‘pseudo-neurotic group’ of children aged 3–5 with anxiety and the 
‘pseudo-psychopathic or antisocial’ aged 10–118. Bender also addressed diagnostic 
continuity and concluded that most children with schizophrenia would continue with 
the same disorder in adolescence and adulthood8.  
 
6 
Throughout the twentieth century, the descriptions and classifications of 
schizophrenia in children and adolescents have been very heterogeneous with a lack 
of specificity. This is evident in the criteria of both the DSM-II and ICD-8. ICD-8 had 
one broad category of ‘childhood psychoses’, including disorders as diverse as 
psychoses, severe personality disorders and what we today would classify as infantile 
autism8. There was, at the time, no consensus regarding whether schizophrenia in 
children even existed8. 
Today, a series of papers on childhood psychoses from 1971 by Israel Kolvin and 
colleagues11-16 are regarded as landmark papers, applying homogenous diagnostic 
criteria to early-onset psychoses and making it possible to distinguish autism and 
childhood schizophrenia  by distinguishing between ‘early-onset psychoses’ (by age 
3) and ‘later-onset psychoses of childhood’ (originating at age 5 or later) 11,17. In their 
papers, they drew on prior work by Leo Kanner and Mildred Creak, in particular, of 
early psychoses, and on the work of B. Fish for late-onset psychotic disorders in 
childhood; however, they also described prior work by James Anthony, Lauretta 
Bender, Bernard Rimland and Michael Rutter as important with regard to moving 
towards a more operational way of classifying the psychoses in childhood11.  
In reading and interpreting clinical descriptions and outcome results of older studies, 
these shifts in concepts and descriptions are important to bear in mind18. The various 
concepts and descriptions of childhood psychoses and schizophrenia throughout 
history result in difficulties with using older studies of childhood psychoses for 
epidemiology purposes. The 42 year follow-up study by Remschmidt et. al.10 serve as 
an example – the study included patients diagnosed between 1920 and 1961 with 
VEOS (including patients up to the age of 14 years) and re-evaluated all case records 
according to ICD-10 classification – only 50% of the original sample met ICD-10 
criteria for schizophrenia and only 18% of the non-schizophrenia cases were even in 
the schizophrenia spectrum.  
 
CLINICAL PRESENTATION AND CHARACTERISTICS OF EARLY-
ONSET SCHIZOPHRENIA 
Studies and reviews have found and described similarities between EOS and AOS in 
terms of the core symptoms of schizophrenia19,20, but developmental variations in the 
clinical presentation must be considered20,21. Delusions in children are often vague 
and less elaborated than seen in adults19,22, and it is important for the clinician to 
distinguish psychotic delusions from vivid imagination and developmental delay in 
reality testing11. Especially in VEOS, imaginary friends can be part of normal 
development20,23. Assessment of logic, loosening of associations and other formal 
thought disorders must also take maturity and IQ into account. Children’s way of 
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expressing themselves can be different from adults’ use of language in terms of 
cohesion, logic and symbolic use 20,23. 
In terms of clinical characteristics, patients with EOS have been found to have more 
premorbid difficulties24-27, potential higher genetic loading28-31 and more cognitive 
dysfunctions 32-34 than patients with AOS. Furthermore, patients with EOS more often 
have insidious onset, and are more frequently profoundly affected by negative 
symptoms and disorganization20. With a long insidious onset in a young age, some 
children with early onset may interpret their symptoms as normal and ego-syntonic 19. 
Children and adolescents often have longer duration of untreated psychosis (DUP) 
than adults 27,35, which also may be influenced by such ego-syntonic symptoms, not 
prompting the individuals to seek help.  
Very-early-onset schizophrenia (VEOS) is by many considered a more severe 
disorder than both adolescent-onset schizophrenia and AOS, with both more 
intellectual deterioration, a more chronic long-term course characterized by negative 
symptoms and with a highly unfavorable outcome17,36. VEOS seems to be associated 
with greater heritability 17. In contrast to adult- and adolescent-onset of the disorder, 
males are overrepresented in VEOS, with studies describing ratios of 3–5:110.  
 
OUTCOME OF SCHIZOPHRENIA 
Outcome of schizophrenia has been studied in adults for decades and several reviews 
of the outcome of first-episode schizophrenia or first-episode psychosis (FEP) exists37-
40. 
Hegarty et al. reviewed 320 studies of adults with schizophrenia with a total of 
approximately 50,000 patients, published between 1895 and 1992 with a mean follow-
up of 5.6 years and described considerable improvement in 40%40. Loss to follow-up 
across the cohorts ranged from 10& to 30%.  
Menezes et al. included 37 studies and 4,100 patients with FEP in their meta-analysis 
of outcome, based on studies published between 1966 and 200337. Mean follow-up 
was 3 years. Studies used different categorizations and definitions of outcome, but 
‘good’ and ‘poor’ were common categories. Of the studies using these categories, 
good outcomes were reported in 42.2% and poor outcomes in 27.1%. The authors 
concluded that the outcome of FEP may be more favorable than previously reported 
and suggested that the reasons for this may be an over-representation of chronic, 
treatment-refractory patients in older studies, as well as patients with full recovery or 
otherwise good outcomes dropping out of the studies at a higher rate. Furthermore, 
they pointed to methodological differences in the pooling and comparison of data and 
suggested a globally used definition of outcome for future research. There was no 
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evidence of age at onset, DUP and diagnosis (schizophrenia vs. schizophreniform or 
affective psychosis) to be predictive in terms of outcome, which, as the authors state, 
was unexpected37.   
From the International Study of Schizophrenia (ISoS), Harrison et al. combined 14 
incident cohort studies and four prevalence cohorts, totaling 1633 subjects39, and 
demonstrated the initial 2-year course (‘percentage of time spend experiencing 
psychotic symptoms’) to be the strongest predictor of outcome at 15 and 25 years’ 
follow-up. The rates of globally recovered were fairly high: 56% in the incidence 
cohorts and close to 50% in studies of AOS only39.   
Jobe and Harrow reviewed nine studies in 2005; the studies were from North America 
and ISoS, coordinated by the World Health Organization (WHO), all with a follow-
up time of 10 years or longer38. Poorer outcomes were seen in schizophrenia as 
opposed to other psychotic disorders, as well as non-psychotic disorders; however, 
patients with extended periods of recovery were also seen in the schizophrenia groups 
and very few patients had a progressive, deteriorating course38. In total, 21–57% 
experienced good outcome.  
In conclusion, the knowledge from adult studies on schizophrenia and schizophrenia 
spectrum disorders points to moderate-to-good outcomes in 21-50%, with most 
reporting rates around 40%, although outcome is worse in samples restricted to 
patients with schizophrenia. Studies vary considerable in methodology and outcome 
measures.  
 
OUTCOME OF EOS AND VEOS 
In EOS and VEOS, reviews have pointed to poorer outcomes compared to AOS41-44. 
Our review of outcome of EOS, which will be described more in detail throughout the 
thesis, was published in 2012 in BMC Psychiatry1 (study 1). In the same year, 
Remschmidt and Theisen published a recapitulation with the current knowledge on 
EOS36 and summarized the findings as a very poor prognosis in VEOS, with a typical 
course extending into adolescence and adulthood. Patients with acute onset and 
positive manifestations had better outcome as patients with insidious onset who more 
often have worsening impairment. Premorbid adjustment were stressed as important 
for the long-term outcome, and genetic predisposition likely worsened the outcome36.  
The largest follow-up study to date comparing outcome and age of onset was a 
register-based study conducted in Israel including 12,071 patients, with 1877 patients 
diagnosed prior to 19 years of age45. The study had a median follow-up of 10 years 
and up to 17 years of follow-up, and showed earlier age of first admission 
corresponded linearly to number of hospitalizations, using recursive portioning as the 
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primary statistical method45. Outcome was worse in patients diagnosed prior to 12 
years of age. In total, 82.5% of patients diagnosed prior to the age of 17 had more than 
one admission, which decreased linearly with subsequent older-onset groups, as did 
the number of inpatient days during first admissions and number of annual 
admissions45.  
Some studies, including newer ones, have not been able to show a worse prognosis of 
EOP compared to AOP35, and currently there are indications of a better prognosis for 
EOS and EOP than previously thought 46,47. These studies have been conducted in 
combined treatment settings for early- and adult-onset. Such studies have been sparse, 
as children and adolescents are mostly treated in other facilities than adults, but 
comparing early-onset and adult-onset psychotic disorders from studies in different 
treatment settings can be problematic as study design, interventions and selection may 
differ48. Schimmelmann et al.’s study of patients in The Early Psychosis Prevention 
and Intervention Centre (EPPIC)35 with EOP and adult-onset psychosis described 
minor difference in outcome between the two groups, which were mostly explained 
by confounders– patients with EOP had slightly worse premorbid functioning and 
higher DUP than patients with AOP (26 vs. 9 weeks), although DUPs were generally 
short in this study35. White et al.49 also compared patients with EOP and AOP in the 
same sample and replicated the finding of longer DUP (125 weeks vs. 68 weeks) and 
found no differences in symptom severity. Joa et al.50 compared patients with EOP 
and AOP patients from the TIPS (‘Early recognition and treatment of psychoses’) 
study in Norway and replicated the finding of longer DUP in patients with EOP. 
Furthermore, higher rates of lifetime suicidality (plans or attempts) were reported for 
patients with EOP. Thirty-five percent of the EOP sample was initially treated as 
outpatients versus only 16% in the AOP sample. The authors concluded that the 
clinical picture EOP may look like a milder form of schizophrenia due to a more 
insidious onset and less clear-cut psychotic symptoms. At the two-year follow-up the 
EOP and AOP patients in the TIPS study did not differ on suicidality, remission, 
substance use, number of patients on antipsychotic medication and hospitalization, 
social and occupational functioning46.  
Most studies reporting a better prognosis for patients with early-onset are not 
restricted to EOS but often include schizophrenia spectrum disorders. As 
schizophrenia is associated with worse outcomes than other psychotic disorders1,38,39, 
this could bias studies. However, Immonen et al. published a meta-analysis in 2017 
studying the effect of age of onset on outcome, by only including studies with patients 
with both EOS and AOS48; and  samples were required to have at least 80% of patients 
with schizophrenia, schizophreniform, schizo-affective or delusional disorder. The 
conclusion from pooling data from 75 studies was that early age of onset had a 
negative effect on some outcomes (more hospitalizations with higher frequency, more 
relapses, negative symptoms, poorer social/occupational functioning and global 
outcome). All though these were important overall measures, all effect sizes were 
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small (<0.2) and the authors concluded that, on some outcomes, age of onset has a 
small but significant effect 48.  
 
FACTORS RELATED TO PROGNOSIS 
Premorbid functioning plays an important role in the course and prognosis of the 
disorder. It is well established that patients with a prior high level of functioning with 
regard to intellectual capacities and abilities for social functioning and integration 
have a better prognosis than children and adolescents who prior to onset of psychosis 
suffered from either intellectual impairment or poor social relations and 
communication skills36. Prognosis also seems to be worse if there is a family history 
of schizophrenia. DUP is a well-researched area, and reviews report longer DUP to 
be associated with poorer outcomes51,52 and the ability to efficiently treat the psychotic 
symptoms52,53.  
Ballageer et al. conducted a study directly comparing clinical characteristics of EOS 
and AOS in patients aged 19–30 years, and showed many similarities in symptoms 
and clinical presentations between the two, but differences in several of the parameters 
that may predict a poorer outcome27. The sample consisted of patients with first-
episode psychotic disorders (schizophrenia spectrums disorders, substance-induced 
psychoses, affective psychoses and other, non-affective psychoses) and 201 patients 
were included, of these 82 had early-onset psychosis (EOP). EOP was defined as the 
onset of psychotic symptoms between 15 and 18 years of age – a slightly older age 
cut-off than most studies of EOS/EOP – including the definition of EOS used in this 
thesis. Patients were thoroughly assessed by experienced psychiatrists and a master in 
psychology. Many similarities were found: premorbid functioning until the age of 15, 
adverse effects of medication, length of prodrome or duration of untreated illness 
(defined as onset of any psychiatric symptoms), measures of hallucinations, delusions, 
formal thought disorder or global scores on Scale for Assessment of Positive 
Symptoms (SAPS), and avolition, anhedonia, alogia, attention and global scores on 
Scale for Assessment of Negative Symptoms (SANS), proportion with substance use, 
anxiety or depression27. However, patients with EOP differed on measures specifically 
associated with poorer outcome – longer DUP (103 weeks vs 46 weeks, p=0.022), 
more bizarre behavior (76.5% vs. 60.5%, p=0.01 and the core negative symptom of 
affective flattening being more severe and affecting more patients (2.52 vs. 2.13, 
affecting 52.4% vs. 37%); and more EOP patients also had primary negative 
symptoms.  
Furthermore, the efficacy of antipsychotic medication may be lower in EOS 54, and 
patients tend to be more sensitive to side effects that may occur more frequently 55. 
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In the past few years, two meta-analyses focused on predictors of outcome in EOS 
and EOP26,56. Stentebjerg-Olesen et al. conducted a systematic review of clinical 
characteristics and outcome predictors of EOP57. The review included 35 studies from 
28 independent samples (n=1506) with a mean age <19 years at baseline, including 
primarily schizophrenia and schizophrenia spectrum disorders (89%), but also a 
smaller number of patients with affective, substance and organic psychoses. Mean 
follow-up was 17 months. Premorbid adjustment was positive correlated to outcome 
at 1–4 years with regards to social functioning, quality of life, global functioning and 
remission, and illness severity measured by CGI-S were lower and negative symptoms 
less prominent with better premorbid adjustment. Díaz-Caneja et al.26 reviewed 75 
studies of EOP in a systematic review using multivariate models. EOP was defined as 
psychotic illness in childhood or adolescence. In four of the studies, the upper age 
limit was >18 years of age, but the mean age was below 18. The focus of the review 
was not on the final outcome of EOP, but instead on predictors of outcome. Longer 
DUP was found to predict worse clinical, functional, and cognitive outcomes. The age 
of onset within these early-onset samples did not prove to be a consistent predictor of 
outcome in the multivariate models. Gender was also not consistently associated with 
outcome. Having a low IQ at baseline predicted worse functional outcome and higher 
likelihood of being diagnosed with schizophrenia. Remission was associated with 
acute onset or shorter DUP as well as higher baseline functioning. The authors 
summarize that patients with EOP with poorer premorbid adjustments and negative 
symptoms at baseline are at risk of poor outcomes.  
DUP, premorbid functioning, intellectual functioning, mode of onset and family 
history of schizophrenia are found to be related to prognosis in both child-, adolescent- 
and adult-onset of schizophrenia26,27,57,58.  
Summarizing, from studies, meta-analyses and literature on EOS in general, there is 
agreement that the following are associated with worse outcomes in EOS / EOP: 
Longer DUP and insidious onset, profound negative symptomatology at baseline, 
genetic predisposition, poor premorbid adjustment, cognitive dysfunctions or low IQ 
and schizophrenia diagnosis compared to other disorders from the schizophrenia-
spectrum, while remission, recovery and better outcomes were associated with acute 
onset. Effect of gender on outcome is not clear; some meta-analyses do not find a 
consistent association26, while our review found poorer outcome for males1, but the 
register-based study did not find a consistent association between sex and outcomes 
After having outlined some of the literature and knowledge of EOS in terms of both 
clinical characteristics, outcome and factors related to outcome, I will now move on 
to the validity of schizophrenia diagnoses.  
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VALIDITY OF DIAGNOSES 
Validity can be described and measured in several ways, common concepts are 
sensitivity, specificity, positive predictive value and negative predictive value, which 
all try to test proportions of positive and negative results, either focusing on the chance 
of being right or the risk of being wrong.   
Sensitivity and specificity are statistical measures to assess performance of a binary 
test. Sensitivity measures the proportion of patients diagnosed correctly with the 
tested measure. Specificity measures the proportion of patients who do not have the 
disorder in question and are correctly identified as such.  
Positive predictive value (PPV) and negative predictive value (NPV) are also 
measures of performance, but unlike sensitivity and specificity, PPV and NPV are 
affected by the prevalence; if the prevalence is high, PPV will be higher and vice 
versa. PPV is often used for diagnostic stability to measure the probability of the same 
diagnosis being given at follow-up.  
The terms validity and reliability are sometimes, erroneously, used interchangeably. 
They are two different concepts, all though to find the best assessment tools, it is 
imperative that they correlate. Reliability measures consistency, while validity tells 
us if we are measuring what we think we are. It is often exemplified by darts, as in 
Figure 1. 
For example, if someone had the idea that we could diagnose schizophrenia by 
measuring shoe size, the measurement would likely be extremely reliable – all ratings 
would be very close to each other and not require extensive training, and consistency 
close to perfection, at least in the adult population. However, the validity would be 
very low – even the general population would oppose this measurement of 
schizophrenia.  
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Figure 1: Validity and reliability exemplified. 
 
 
 
 
 
 
 
 
 
 
 
 
Reliability refers to the degree to which the construct can be measured adequately. 
Interrater reliability refers to the degree different people will reach the same 
conclusions, and intrarater reliability, the degree to which one rater will reach the 
same conclusion if he/she were to measure the same construct on a different day. 
Reliability are also sometimes called precision or concordance.   
The optimal method for assessment of schizophrenia would have both high validity 
and reliability – in such cases, it would be fairly easy to train clinicians to use a method 
that would enable them to arrive at the same conclusion (good reliability) and the 
conclusion would match the reality (good validity).  
How to calculate sensitivity, specificity, PPV, NPV are shown in figure 2.  
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Figure 2: Diagnostic test evaluation 
  
Patients with a disease or disorder (as 
confirmed by gold-standard)* 
  
Condition  
positive 
Condition  
negative 
Screen 
test 
outcome 
Test 
positive 
True positive  
(TP) = 54 
False positive  
(FP) = 8 
Positive predictive 
value 
    = TP / TP + FP) 
    = 54 / (54 + 8) 
    = 0.871 (87.1%) 
Test 
negative 
False negative  
(FN) = 2 
True negative 
(TN ) = 9 
Negative predictive 
value 
    = TN / (FN + TN) 
    = 8 / (2 + 8) 
    = 0.818 (81.8%) 
  
Sensitivity 
= TP / (TP + FN) 
= 54 / (54+2) 
= 0.964 (96.4%) 
Specificity 
= TN / (FP + TN) 
= 8 / (8+9) 
= 0.529 (52,9%)   
* The example is calculated from the findings in Makïkyro et al.’s study59. 
 
DIAGNOSTIC VALIDITY OF SCHIZOPHRENIA IN REGISTERS 
Internationally, as well as in Denmark, several mental disorders have been 
investigated in healthcare registers in order to assess accuracy of diagnostic 
registration as well as diagnostic validity60-69. The assessment of a register’s 
usefulness for research studies should rely on two cornerstones: 
1) The concordance between clinical and register diagnoses.  
2) The validity of clinical diagnoses compared to diagnostic criteria.  
The first is a matter of the preciseness and accuracy of the coding of diagnostic 
classification in the register. Some mistakes are unavoidable, but it should be 
investigated whether errors are random without any specific bias or if there are 
inherent misunderstandings in the coding or inexpedient local procedures. In the 
DPCRR the diagnostic codes are automatically generated from the psychiatric 
hospitals, so errors due to forgetfulness are avoided. The agreement between clinical 
and register diagnoses are fairly easy to assess; a review of the discharge summaries 
compared with DPCRR diagnoses would be sufficient.  
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The latter requirement of validity of clinical diagnoses is more difficult to assess as it 
involves an evaluation of the assessment conducted in the clinic. Adequate adherence 
to diagnostic criteria requires experience and competence by the clinician, as well as 
his/her willingness to follow the diagnostic classification system used at a certain 
time.  
Byrne and colleagues investigated validity of the administrative data in the registers 
in a review of studies between 1966–200470; 14 validity studies of register-data were 
found, with five focusing specifically on schizophrenia59,61,64,69,71. Generally, the 
studies drew positive conclusion about the validity. In the studies reporting solely on 
schizophrenia, a Swedish study described 86% true positives with a broad definition 
of schizophrenia and 76% with a narrow definition69, a Danish study 66% true 
positives and sensitivity as 0.4064, a Swedish older study as 76% true positives61 , one 
Finnish study 48% false negatives, specificity of 1 and sensitivity of 0.5271 , another 
Finnish study 93% true positives, a PPV of 0.87 and NPV value of 0.82 (exemplified 
in Figure 2)59. In studies examining several disorders, schizophrenia generally had 
better validity than the other disorders, with a Finnish study reporting accuracy of 
99% in schizophrenia72.  
In Denmark, reliability of schizophrenia diagnoses have been investigated by 
Jakobsen et al. who documented high sensitivity (93%) and PPV (87%) of 
schizophrenia and for schizophrenia spectrum disorders as a broad entity (98%) in a 
study with 100 randomly sampled from a research biobank of which the majority were 
evaluated using both interview and medical record assessment73. Another study 
validated schizophrenia diagnoses registered in the DPCRR in 2009 by rating of 
psychiatric records and found the register diagnosis to be correct in 89.7–97.55% of 
the cases62.  
Prior to study 2 (submitted), only one study has validated EOS and EOP – the Swedish 
study by Dalman et al. published in 2002, validating schizophrenia diagnoses from 
the Swedish National Inpatient Register in patients diagnosed prior to age 2069. One-
hundred patients with an ICD-9 diagnosis of schizophrenia syndrome (71 with narrow 
schizophrenia) were included, and 36 of them had EOS69. The validity between 
patients with EOS and AOS were similar (14% vs. 15% false positives).  
All though no other methodological validity study of EOS seem to exist, the 
diagnostic process in the important work with the NIMH-COS cohort led by Judith 
Rapoport et al.7 deserves mentioning.  
In NIMH-COS, the investigators thoroughly reported their process of diagnosing and 
validating the referred patients, all of whom were referred with a tentative diagnosis 
of schizophrenia. If the initial screening process (telephone screening followed by 
clinical and structured interviews) yielded a provisional diagnosis of COS, the child 
would be admitted to a highly staffed inpatient unit for a medication-free period of up 
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to 3 weeks. Of all the patients referred, only 5% had the diagnosis confirmed74. Of the 
patients admitted with a provisional COS diagnosis, it was ruled out for almost 40%25. 
The researchers of the NIMH-COS cohort have underlined that diagnosing VEOS is 
a time-consuming process with high rates of false positives25, which has also been 
confirmed by other studies75.  
DIAGNOSTIC STABILITY IN SCHIZOPHRENIA 
A concept related to diagnostic validity, but not identical to, is diagnostic stability: the 
proportion of patients who retain the same diagnosis over time. For a disorder like 
schizophrenia, we would expect a high level of diagnostic stability as schizophrenia 
is known as a disorder with some chronicity, but we would not expect 100% 
diagnostic stability as some patients do have full remission, and a 100% stability 
measure might indicate that diagnoses are carried forward without new considerations 
or assessments.  
Research confirms schizophrenia as a disorder with a high diagnostic stability over 
time, also known as a high PPV for long-term outcome76. In adult studies, Whitty et 
al. reported a long-time PPV of 96% – 72 in 75 patients with schizophrenia at baseline 
retained the diagnosis at follow-up after four years77. An older study by Amin et al. 
reported PPV of 83% in patients diagnosed with schizophrenia at onset measured at 
the three-year follow-up78.  In early-onset samples, diagnostic stability have been 
reported in 66% and 100% of the patients79-83:  Jarbin and Knorring79 traced 68 former 
patients who had been diagnosed with a first-episode EOP 10.5 years previously; 
patients with a diagnosis with schizophrenia were all diagnosed with schizophrenia as 
a lifetime diagnosis at follow-up (PPV of 100%), and 28 of 29 in the schizophrenia 
spectrum retained a diagnosis in this spectrum at follow-up (PPV of 96.5%). Hollis 
and colleagues conducted a follow-up study on 110 patients with first-episode EOP, 
51 of them with EOS. After 11.5 years, schizophrenia had a PPV of 80%80. In the 
Child and Adolescent First-Episode Psychosis Study (CAFEPS), the researchers used 
a prospective method for assessing diagnostic stability82. The participants, aged 9–17 
years, all had EOP and were assessed with the Kiddie Schedule for Affective 
Disorders and Schizophrenia for School Aged Children (K-SADS)84,85 at baseline and 
again after 2 years. The diagnostic stability of a diagnosis in the schizophrenia 
spectrum was 90% (n=40), and for schizophrenia 100% (n=5). A Polish study 
described diagnostic stability of 78% in EOS assessed after 8 years of follow-up81. 
Thomsen studied EOS in the Danish registers, including all patients (n=312) with EOS 
in the period 1970-199383. Diagnostic stability was assessed for the patients with later 
admissions, and 33% had admissions for other disorders. In the subgroup who had at 
least 10 years of follow-up, schizophrenia was confirmed at a later admission in 
64%83.   
Owing to the low incidence and prevalence of EOS, many clinicians in child and 
adolescent psychiatry are less experienced in diagnosing EOS. To exemplify, 
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approximately 100 patients are diagnosed with EOS each year in Denmark86-88, a 
country with 5.7 million inhabitants, and although the number of patients with EOS 
has been increasing89, it is still a small population compared with the larger group 
with AOS. The prevalence of VEOS is even smaller, as I will highlight in studies 2 
and 3, to a degree that makes VEOS close to impossible to study quantitatively in a 
country as small as Denmark. To account for the low prevalence and therefore limited 
experience in regular clinics, as well as to establish a larger cohort for the purpose of 
research in assessment, clinical characteristics and treatment, the NIMH has supported 
a large-scale study in the USA – the aforementioned NIMH-COS cohort – in which 
children from across the country are assessed and treated in the same clinic. The 
NIMH-COS study has been enrolling patients since 1991 and is still ongoing. Despite 
the expertise level of assessment at the COS-Study clinic, inpatient assessment with a 
drug washout period is still warranted in many cases in order to avoid false-positive 
cases90.  
Despite the challenges of low prevalence and symptom presentation being influenced 
by developmental age, there is general agreement that schizophrenia can be reliably 
diagnosed in children and adolescents, but a thorough assessment by experienced 
clinicians is essential20,25, especially for VEOS25,90.   
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CHAPTER 2: METHODS 
The thesis is based on three studies with three different types of study design and data 
selection:  
- Study 1 is a literature review of the outcome of EOS, based on PRISMA 
guidelines for study selection, inclusion and design91. The study used 
quantitative measures to combine findings from the studies selected. 
- Study 2 is a retrospective validation study based on psychiatric records of 
patients diagnosed with EOS. The study used experienced clinicians to rate 
the validity of the schizophrenia diagnosis based on the written material in 
the records. Interrater reliability was assessed. Concordance between 
register-diagnosis and clinical diagnosis in the records were assessed as well 
as validity of the clinical diagnoses as evaluated by the raters. Symptom 
distribution, clinical characteristics and rates of childhood adversities were 
described.  
- Study 3 is a register-based study of outcomes of schizophrenia. The study 
included patients diagnosed with schizophrenia between 1996 and 2012 
before the age of 40 years and compared patients with EOS and AOS on 
measures related to psychiatric outcome and outcomes of functioning. 
Descriptive analyses and regression models adjusting for confounding 
covariates were conducted.  
 
The details of the methods used in each study are outlined below.  
 
STUDY 1: SYSTEMATIC REVIEW OF OUTCOME OF EOS 
Study 1 is a systematic review of the outcome of EOS using quantitative measures. 
The literature search was conducted in PsycINFO, PSYCarticles and Pubmed, 
additional papers were included through hand-search. The search terms were the 
following present in title or abstract: adolescent onset schizophrenia, childhood onset 
schizophrenia, very early onset schizophrenia, early onset schizophrenia. 
Inclusion criteria: 
- Articles published after 1979 in the English language  
- Sample consisted of patients with EOS or a combination of patients with EOS and 
EOP 
- Mean age ≤18 years. 
 
20 
Exclusion criteria:  
- Single case studies 
- Studies without broad outcome measures, which could be classified as ‘good’, 
‘moderate’ or ‘poor’ 
- Studies only reporting a mean on outcome or with unclear outcome criteria 
- Studies without internationally accepted diagnostic criteria (ICD or DSM) 
- Studies with follow-up <1 year. 
The literature search was conducted according to PRISMA guidelines91 and a 
flowchart of the search process is presented below.  
Figure 3: Flowchart of literature search 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
21 studies included in  
quantitative synthesis 
96 full text publications 
 assessed for eligibility 
646 publications screened 
980 publications 
40 additional 
publications, 
identified through 
other sources 
- 455 publications identified 
through PsycINFO/ 
PsycARTICLES 
- 485 records identified 
through Pubmed 
50 studies included in qualitative 
synthesis 
46 full text publications 
excluded owing to:  
- No schizophrenia 
patients in sample.  
- Mean age >18 years 
- Follow-up <1 year 
- Case reports  
- No follow-up 
- Only mean outcome 
scores 
- No functional outcome 
scores 
 
- 444 excluded based on 
title 
- 106 excluded based on 
abstract 
334 duplicates removed 
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Outcome measures 
The reported outcome of the studies were categorized into ‘General Functioning 
Scale’ (GFS) or Study-Specific Functioning outcome (SSF). GFS included Global 
Assessment of Functioning (GAF)92, Children’s Global Assessment Scale (CGAS)93 
or Global Assessment Scale (GAS)94 with all scales running from 0 to 100. Poor 
outcome was classified as scores ≤ 50, moderate as scores 51–70 and good outcome 
as scores >70. SSF outcomes were outcomes defined in the specific study, either using 
a scale or categorical definition of outcome. SSF outcomes were also rated as poor, 
moderate and good based on their outcome measures. The three authors independently 
classified all studies into the three categories. In case of disagreement, a consensus 
decision was made.  
We analyzed differences in studies including only patients with EOS versus studies 
including patients with schizophrenia as well as other psychotic disorders. 
Furthermore, five predicting variables were considered in the analyses for effect on 
outcome: drop-out rates, GFS/SSF measure of functioning, mean duration of follow-
up categorized as ≤ 10 years and > 10 years, sex and time period of diagnosis.  
 
Statistical analyses 
Non-parametric tests were applied due to significant deviations from normal 
distribution. Analyses were conducted on adjusted sample sizes at follow-up 
assessment; weighted percentages were calculated for the reported rates to account for 
difference in sample size. Mann–Whitney tests with Bonferroni adjustments of p-
values for multiple testing were conducted for the five predicting variables. A 
significant p-value was defined as 0.01 and highly significant at 0.002. Spearman’s 
rho95 was used for effect size (0.1-0.29 = small effect, 0.3-0.49 moderate effect, ≥0.5 
= large effect). Data was analyses using SPSS version 2096.  
 
STUDY 2: VALIDATION STUDY OF EOS DIAGNOSIS  
The study was a retrospective review of psychiatric records.  
From ICD-10, codes F20.0-23.0, F20.6 and F20.9 were included, equivalent to 
paranoid schizophrenia, hebephrenic schizophrenia, catatonic schizophrenia, 
undifferentiated schizophrenia, schizophrenia simplex and schizophrenia unspecified. 
The decision to exclusively review schizophrenia records was based on available 
resources, as well as difficulties in blinding diagnostic decisions and considerations. 
Furthermore, no prior validation study of EOS diagnosis in the clinic or using the 
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DPCRR had ever been conducted in Denmark, so to evaluate as many files as possible 
was a priority. 
Sample size 
Psychiatric records from 200 patients diagnosed with schizophrenia before 18 years 
of age as registered in DPCRR. Sample size estimation with regard to adequate power 
was not conducted. This would have been difficult as there is only one study assessing 
validity of EOS which only included 36 patients with EOS69. The number of 200 was 
>20% of the total sample of patients with EOS for the time period; furthermore, it was 
manageable in terms of time and resources.  
Collection of files 
Based on a local pilot study at Aalborg Hospital in the North Denmark Region, the 
design of the study was initially based on discharge summaries. During that period, 
discharge summaries for severe mental disorders in child and adolescent psychiatry 
were often several pages long with a detailed description of symptoms leading up to 
diagnosis, symptoms after initiation of treatment and premorbid characteristics. Using 
only the discharge summary, a majority of the files could be rated with sufficient data.  
The design of the study was changed after retrieval of the first psychiatric records 
from other regions as the degree of detail in the description of psychopathology varied 
too much and sometimes were not mentioned in the discharge summaries.  
In order to have sufficient information for diagnostic classification, the following was 
collected when available: discharge summaries, case summaries, anamnestic material, 
conference notes, observations during inpatient admission and psychological 
assessment with cognitive or projective test material, and semi-structured interviews 
such as the Present State Examination (PSE)97,98 or K-SADS / K-SADS-PL84,85. 
Several attempts were made to locate missing files and material – the search was 
extended to adult archives and other hospitals in the same geographic region.   
Relevant materials were copied and securely stored at the research facility. 
 
The raters 
All six co-raters were child and adolescent psychiatrists with clinical experience in 
psychosis; additionally, the majority had either instigated or participated in research 
of early-onset psychotic disorders 23,99-105. The mean number of years in child and 
adolescent psychiatry for the co-raters were 16.5 years (range 10–28 years). I have 10 
years of experience in child and adolescent psychiatry and have psychologist 
 
23 
specialization in the field. Furthermore, since 2014, I have been managing an 
outpatient clinic (OPUS team) in adult psychiatry for younger adults with incident 
schizophrenia.  
 
Data extraction 
The material from the archives was initially read and evaluated by the primary rater 
(the PhD student, DLV), who selected relevant documents for the co-raters to assess. 
Co-raters evaluated the diagnosis while recording data in a checklist, entailing all 
diagnostic criteria from ICD-10, as well as data regarding onset type, familial 
predisposition, DUP, loss of functioning, substance use, antipsychotic medication and 
whether a semi-structured interview had been used in the assessment (see appendix 
A). Along with the selected documents, the co-raters received a write-up detailing the 
following information if available: prior diagnoses and admissions, psychiatry 
predisposition and intellectual capacity.  
As the primary rater of all files, I extracted demographic and anamnestic information, 
as well as details regarding assessment and functioning (see appendix B). Two 
psychology students re-evaluated the material to check for missing information and 
accuracy. Both psychology students were in their last year at university and had been 
working as psychology interns in a clinic for young adults with incident 
schizophrenia.  
Ratings and extracted data from the psychiatric records were entered into a database 
using EpiData106. The data set was transferred to Stata 14 for analyses107.  
Validity measures 
All records were rated as ‘correct’, ‘maybe’ or ‘incorrect’ based on criteria for an 
ICD-10 diagnosis of schizophrenia. Raters selected ‘maybe’ in cases with insufficient 
information, symptoms being described too vaguely, unclear duration to a diagnosis 
of schizophrenia or the presence of other diagnoses potentially explaining the 
symptomatology. Additional material from the psychiatric record was provided for 
the co-raters when possible, if needed to make a diagnostic decision. When the raters 
chose ‘maybe’, they would further specify if the diagnosis was leaning towards ‘likely 
correct’ or ‘likely incorrect’. Finally, all categories were defined as confirmed 
(‘correct’ and ‘likely correct’) or not confirmed (‘incorrect’ and ‘likely incorrect’).  
In case of disagreement between primary rater and co-rater, the details of the case 
were discussed openly to reach a consensus diagnostic decision. Another rater would 
be involved in case consensus could not be reached. Co-raters did not evaluate records 
from their own region of the country, while I rated all records except for one in which 
I had been involved in the patient’s clinical assessment.  
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The term ‘clinical schizophrenia’ was used for cases in which the psychiatric record 
described the diagnosis as schizophrenia. Cases in which the DPCRR diagnosis of 
schizophrenia did not match the diagnosis described in the record, were defined as 
‘registration errors’. Validity for both clinical schizophrenia and DPCRR 
schizophrenia were evaluated.  
Demographic variables and prior history 
From the data extracted, developmental problems were rated as present if anamnestic 
data in the record described:  delayed language or early interventions due to speech 
problems prior to 5 years of age, social developmental problems prior to age or 
delayed or markedly uncoordinated gross motor functions prior to 5 years of age. A 
formal ICD-10 diagnosis of developmental difficulties was not required. Childhood 
adverse events prior to schizophrenia included parental separation, parental death or 
parental substance use, change of school and unspecified adversities (e.g. witnessing 
domestic abuse, accidents, bullying, homelessness, immigration, parental crime or 
severe parental mental disorder). Presence of trauma included having experienced 
violence, sexual assault or other traumatic experience. Indicators of emotional and 
behavioral problems preceding schizophrenia included presence of self-harm, suicidal 
ideation, suicide attempts, aggressive behavior towards others, history of any criminal 
activity and problems with substance use. 
Statistical analyses 
Diagnostic concordance and validity of DPCRR and clinical schizophrenia were 
analyzed for all available records. Demographic data, psychosocial variables and 
symptom distribution were analyzed for all cases confirmed by raters, as well as those 
present in the clinical psychiatric record. Additionally, the patients were divided into 
cases of VEOS and patients with onset in adolescence (13–17 years). Post-hoc, an 
analysis of diagnostic concordance and validity of in- and outpatient diagnosed 
schizophrenia was undertaken.  
For interrater reliability, Cohen’s kappa (к) was used with Landis and Koch’s 108 scale 
for evaluating the results (к <0 = no agreement, 0–0.20 = slight, 0.21–0.40 = fair, 
0.41–0.60 = moderate, 0.61–0.80 = substantial, 0.81–1 = almost perfect agreement). 
EpiData106 was used to enter all data into a database; Stata 14107 was used for analyses.  
Permissions and ethics:  
Permissions were obtained from Statistics Denmark, the Danish Data Protection 
Agency (journal no. 2013-331-0285), the Danish Board of Health (journal no. 3-3013-
87/1) and the State Serum Institute (journal no. FSEID 00000359). All child and 
adolescent psychiatric departments in Denmark participated by giving access to their 
archives and psychiatric records.  
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STUDY 3: OUTCOME OF EOS IN THE REGISTERS 
Register studies are one of the hallmarks of Danish research and, especially in medical 
and psychiatric research, Denmark is known worldwide for its registers109-112. Along 
with the other four Nordic countries (Finland, Sweden, Norway and Iceland), 
Denmark stands out with its extensive registers following every citizen from cradle to 
grave.  
In the following paragraphs, an overview of the Danish registers will be provided 
before detailing the specifics of study 3.  
THE DANISH REGISTERS, AN OVERVIEW 
Denmark has extensive registers covering a lot of aspects of life. Each citizen born in 
or immigrated to Denmark has a personal registration number. This unique number is 
used in all contacts with the Danish public service, and necessary in daily life to open 
bank accounts, get appointments at the doctor or hospital, receive a library card, take 
out insurance, be employed, receive salaries and pay taxes. In the Danish registers, 
the personal registration number is converted into a unique ID-number to facilitate 
linkage between the registers without compromising data security and anonymity. 
Analyses are conducted via remote access to the server at Denmark’s Statistic with a 
very high level of information security and regulations.  
Figure 4 below provides an overview of the registers used in study 3 and the linkage 
between the registers.  
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Figure 4: Linking the Danish registers to participants in study 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The Danish Civil Registration System (CRS) 113,114  
The Danish Civil Registration System (CRS) contains data on all Danish citizens born 
in Denmark or immigrated after 1st of April 1968 and permits accurate linkage in and 
between registers, as well as linkage of the individual to their family.  
The Danish Psychiatric Central Research Register2 
The Danish Psychiatric Central Research Register (DPCRR) was established in 1969 
as an electronic database and contains data on all psychiatric admissions since 1969 
and onwards. Outpatient contacts were included from 1st of January 1995. The 
coverage of DPCRR is believed to be almost complete. Diagnoses from private 
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practice, however, are not registered in DPCRR, including both private practitioners 
of general medicine, as well as psychiatrists working in private practice. 
The Danish National Patient Register115  
The Danish National Patient Register (NPR), established in 1977, covers all 
admissions to somatic hospitals including both in- and outpatient contacts and 
diagnostic codes from ICD-10. The diagnoses from the psychiatric hospitals have 
been included in the NPR since 1995.   
The Danish Register of Involuntary Admissions and Treatment in Psychiatry   
This register contains data of involuntary admissions and involuntary inpatient stays 
as well as situations where the patient have been restrained or given involuntary 
treatment.  
Population Education Register at Statistics Denmark116  
The Population Education Register at Statistics Denmark contains data on type and 
level of education with a coverage of 97% of Danish citizens born after 1945.  
The Register of Support for Children and Adolescents117 
This register contains information on all children placed out of the home, either with 
or without parental consent. The placement may be in foster care, institutions or 
orphanages and can be a result of problems in the home with violence, sexual abuse, 
substance use or severe mental disabilities or disorders, or the child having special 
needs or severe behavioral disturbance.  
The Danish National Crime Register118 
The Danish National Crime Register contains information on all convictions and 
incarcerations since 1980. The age of criminal responsibility in Denmark is 15 years.   
The Danish Registry of Causes of Death  
The Danish Registry of Causes of Death, established in 1969, provides data on time 
and cause of death according to the W.  
The Housing and Building Register119 
The Housing and Building Register was established in 1977 and notes the 
accommodation status of all inhabitants in the country. The register provides data on 
the type of housing, e.g. houses, apartments or institutions.  
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The IDA Database120,121 
The IDA Database contains information about the total population of Denmark, 
including employment and primary source of income and activity. 
The DPCRR2 was used for sample selection as well as psychiatric data for both 
patients and their parents, the Danish Register of Involuntary Admissions and 
Treatment in Psychiatry was used to determine if the patients had experienced 
involuntary admissions and hospitalizations and the frequency, Population’s 
Education Register at Statistics Denmark116 was used to determine level of education 
for patients and their parents, The Danish Registry of Causes of Death122 was used to 
determine premature end of follow-up, The Housing and Building Register119 was 
used to collect data on institutionalization and parental separation, and the IDA 
Database121 for data on primary source of income.  Data on childhood adversities prior 
to a schizophrenia diagnosis were available from the Danish National Patient 
Register115 in order to determine parental long admissions to somatic hospital, The 
Register of Support for Children and Adolescents117 was used to determine rates of 
out-of-home care during childhood, The Danish National Crime Register was used to 
assess if parents had been incarcerated, The Danish Registry of Causes of Death to 
assess parental death and finally we assessed parental separation by use of The 
Housing and Building Register. 
 
SAMPLE DEFINITION 
The sample in study 3 was defined as patients with a first-episode ICD-10 diagnosis 
of schizophrenia in the DPCRR prior to age 40 in the period 1996–2012. The 
schizophrenia diagnostic codes included F20.0 paranoid schizophrenia, F20.1 
hebephrenic schizophrenia, F20.2 catatonic schizophrenia, F20.3 undifferentiated 
schizophrenia, F20.6 simple schizophrenia and F20.9 schizophrenia, unspecified. 
Patients with a previous diagnosis of schizophrenia in ICD-8 were excluded. 
Emergency rooms diagnoses were excluded due to a reduced diagnostic reliability. 
Research has shown that the reliability of emergency room diagnoses is acceptable 
for broad diagnostic groups, such as depression, psychoses and alcoholism, but should 
be avoided for more specific subtypes such as schizophrenia123.  
The patients were followed in the registers until the end of 2014 or death, whichever 
came first. Age of onset was defined as the first day of the psychiatric in- or outpatient 
contact in which schizophrenia was diagnosed. The patients were divided into EOS 
or AOS, depending on diagnosis before or after age 18, see flowchart for sample 
selection, figure 5. 
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A control group was added in order to compare baseline and demographic variables. 
The control group was a random sample of the Danish population from the CRS, 
matched to the cases on birth year and alive at the time the case received the 
schizophrenia diagnosis. Three controls per case were matched. Controls were 
excluded if they developed schizophrenia but were allowed to have other psychiatric 
disorders, to achieve a sample representative of the general population. Matching was 
conducted utilizing the CRS113,114 and the DPCRR2,124.  
Figure 5: Sample selection from DPCRR and CPR 
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OUTCOMES 
The primary outcomes were number of inpatient days for the first 2 years after 
diagnosis and the annual number of inpatient days for the remaining follow-up time.  
Secondary outcomes included the proportion of patients never admitted, number of 
readmissions among patients diagnosed as inpatients, annual number of admissions, 
length of first admission at or after schizophrenia diagnosis, mean length of 
admission, proportion of patients with heavy use of inpatient days defined as a mean 
of >40 annual inpatient days after the initial 2 years, and diagnosed substance use 
disorders during follow-up. Functioning outcomes consisted of having completed 
education at a level above law-mandated school, main source of income and living in 
an institution during the last year of follow-up. The functioning outcomes were 
restricted to patients with a minimum of 5 years of follow-up, and education and 
income measures furthermore restricted to patients aged 23 or older at the end of 
follow-up in order not to bias against the EOS sample.  
 
Statistical methods 
Primary outcomes of inpatient days for short- and long-term were analyzed using 
zero-inflated negative binominal (ZINB) analyses. This statistical model was 
appropriate due to an excess of patients with zero inpatient days, both in the short- 
and long-term analyses. Test of fitness in the data set were conducted utilizing the 
vuong zip option in Stata, which pointed to the ZINB model as being superior to the 
standard negative binomial model. Furthermore, the countfit option developed by 
Long & Freese125 was conducted, and ZINB was preferred over the negative binomial 
regression model, Poisson regression and zero-inflated Poisson (p <0.001). Gender, 
year of diagnosis, placement out-of-home during childhood and substance use 
disorder during follow-up were used as covariates. Year of diagnosis is often used in 
register studies to control for structural changes, such as the shift from inpatient 
psychiatry to community-based outpatient treatment – the ‘de-institutionalization’ – 
with a substantial reduction in the number of psychiatry beds, a trend that has also 
been described in other countries 126-128. Sensitivity analyses were conducted on four 
different subgroups to test the robustness of findings and control for possible 
misclassification.  
Secondary outcome measures were analyzed with univariate statistics: t-test, chi-
square and one-way ANOVA. Level of significance was defined as a p-level <0.05.  
All analyses were conducted by remote access to Statistics Denmark’s server, utilizing 
Stata 107. The sampling was conducted with R using an algorithm to ensure the best 
possible match 129-131. 
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CHAPTER 3: RESULTS 
STUDY 1: SYSTEMATIC REVIEW OF OUTCOME OF EOS 
In total, for the quantitative synthesis in our systematic review1, we included 21 
studies28,79,132-150, totaling 716 patients at follow-up with sample sizes between nine 
and 81 patients (mean 44.4, SD 19.4). Males were slightly overrepresented (56.5%). 
Among the studies, 13 consisted of only patients with EOS (n= 393) and eight 
consisted of EOS and other psychotic disorders (n = 323), mostly schizophrenia 
spectrum disorders, only one study also included affective psychoses148. Follow-up 
varied between 1.5 and 42 years (mean 14.4, SD 11.4). Mean age at onset was reported 
in 16 studies (mean 14.9, SD 1.5), but five studies only reported age ranges. The 
majority of the studies only included patients < 18 years of age; in six studies few 
older patients were included (maximum 20 years at the time). All studies had a mean 
age of onset <18 years. Ten studies used global functioning scales (GFS) and 11 used 
Study Specific Functioning (SSF) outcomes. Dropout rates were described in 17 
studies and varied from 0% 135,147,150 to 59%134.  
The studies were heterogeneous in terms of design, sample size, duration of follow-
up, type of evaluation and dropout rates. Since the studies were conducted across a 
wide time period (1920–2010), diagnostic classification changed considerably during 
follow-up.  
Ratings of outcome 
In the full sample, 17.2% had good outcome, 28.2% moderate and 54.6% poor 
outcome. In studies containing only patients with EOS, 15.4% had a good outcome, 
24.5% a moderate outcome and 60.1% a poor outcome. In studies containing patients 
with both EOS and EOP, 19.6% had a good outcome, 33.6% had a moderate outcome 
and 46.8% had a poor outcome (p<0.001). The effect sizes between the EOS samples 
and the combined samples were moderate.  
The three authors were in total agreement 19 of the 21 studies. For the remaining two 
studies, two of the authors agreed on the rating, which was considered as consensus.  
Outcome by measures of functioning 
                                                          
 In the paper from study 1, the numbers are erroneously listed as EOS=422 and studies with 
mixed schizophrenia spectrum disorders=294. 
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In studies using GFS measures of functioning, more patients with moderate outcomes 
were found in EOS samples, whereas more patients in studies with mixed EOP and 
EOP had poor outcomes as measured by GFS. The effect sizes were small.  
Duration of follow-up 
Longer duration of follow-up was associated with worse outcomes in studies 
including only patients with EOS (poor outcome 67% vs. 51%; p<0.001). The effect 
sizes for the differences in good and poor outcomes depending on follow-up duration 
were moderate (0.43–0.45). In studies with mixed psychotic disorders, the findings 
were different – slightly more patients had good outcomes in studies with long follow-
up (20.8% vs. 16.4%; p=0.001) and fewer patients with moderate outcomes (32.1 vs. 
37.5%; p<0.001), however the effect sizes for the schizophrenia spectrum samples 
were small.  
Sex 
Only five studies reported separate results for males and females (n=190). In the 
analyses of these studies, males had more poor outcomes (59.2% vs. 39.5%; p=0.002), 
whereas females had more good outcomes (23.2% vs. 17.6%; p <0.001) and moderate 
outcomes (37.3% vs. 23.2%; p<0.001). Furthermore, we investigated sex proportions 
by comparing the six studies with <50% males to the 14 studies with >50% males and 
found the same results: the proportion with good and moderate outcomes were lower 
in studies with a male predominance, whereas these studies had a higher proportion 
of poor outcomes (p≤0.005). 
Drop-out rate 
Seventeen studies reported how many patients dropped out during the studies. We 
dichotomized the attrition rates from the studies at the median and classified studies 
into having a high or low attrition rate (<28% and >28% drop-out rates, respectively). 
The rates of good outcome were the same, regardless of attrition rate, but more 
patients had poor outcomes in studies with high rates of drop out and more patients 
had moderate outcome in studies with low drop-out rates (p<0.001), the effect size 
was small.  
Time period of diagnosis 
Studies were dichotomized into studies including patients diagnosed before and after 
1970 (n=234) and studies including only patients diagnosed in 1970 or later (n=461). 
Outcome appeared to improve in studies including patients diagnosed in a later time 
period, especially in studies with mixed psychotic disorders where the proportion of 
poor outcomes decreased from 78.5% in studies with patients diagnosed prior to 1970 
(only one study, n=28) to 46.8% in studies with patients diagnosed after 1970 
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(p<0.001). In studies of patients with EOS only, the proportion of poor outcomes also 
decreased in newer studies (from 66.6% to 59.3%; p<0.001).  
 
STUDY 2: VALIDATION STUDY OF EOS DIAGNOSIS  
DIAGNOSTIC CONCORDANCE AND VALIDITY 
Psychiatric records from 178 patients with a DPCRR diagnosis of EOS were retrieved 
(89%). The remaining 22 records were missing (11%). For the missing records, 12 
were completely missing, but for 10 records it was clear schizophrenia was not a 
registration error.  
Of the 178 records retrieved, the agreement between register-based and clinical 
diagnosis was 88.8%. In 20 records, the clinical diagnosis described in the record were 
not identical with the register-based schizophrenia diagnosis – these were registration 
errors. In 16 of the 20 registration errors, schizophrenia had been considered during 
the psychiatric contact, and the patient had been referred from out- to inpatient setting 
for further assessment to rule out schizophrenia, and the patients were later discharged 
without a schizophrenia diagnosis. In two of the registration errors, the raters actually 
confirmed the register-based diagnosis of schizophrenia to be correct.  
In total, of the 178 register-based schizophrenia diagnoses, the raters confirmed 134 
records as schizophrenia (75.3% validity), and 149 as in the schizophrenia spectrum 
(83.7%).  
Among the 158 records with clinical schizophrenia – thus removing the registration 
errors – the raters confirmed 132 as schizophrenia (83.5%) and 145 as schizophrenia 
spectrum disorders (91.8%).  
Inpatient vs. outpatient diagnoses 
EOS diagnosed during inpatient treatment had a considerably higher validity than 
diagnoses from outpatient settings. Of the clinical EOS diagnoses, 71.9% were 
confirmed in patients diagnosed as outpatients and 91.5% in inpatients. Register-
based schizophrenia had even lower validity in outpatient settings, owing to a higher 
rate of registration errors (19% vs. 5%). The raters confirmed only 59.5% of DPCRR 
EOS in outpatient setting vs. 87.9% from admissions (p<0.001). 
Among the 26 clinical schizophrenia diagnoses that were not confirmed by raters, the 
raters diagnosed other disorders with psychotic symptoms in 100% of the non-
confirmed records from inpatient settings (n=8), but only 55.6% of the outpatient 
settings (n=18).  
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Distribution of ratings and interrater reliability 
The ratings are outlined in Figure 6, with three steps of validity classification: step 1:  
‘correct’ – ‘maybe’ – ‘incorrect’, step 2: ‘correct’ – ‘likely correct’ – ‘likely incorrect’ 
– ‘incorrect’, and step 3: ‘confirmed’ – ‘non-confirmed’. 
Figure 6: Validation ratings of all retrieved psychiatric records (n: 178) 
 
Cohen’s kappa for interrater reliability was substantial, with weighted kappas for the 
three steps of validation categories of 0.78, 0.79 and 0.83, respectively. The raters 
were in complete agreement or able to reach consensus in all cases except for one, in 
which a third rater was involved, who read and rated the material blinded to the initial 
ratings.  
DEMOGRAPHY AND PRIOR HISTORY OF CONFIRMED RECORDS 
Among the 132 psychiatric records with both DPCRR schizophrenia, clinical 
schizophrenia and confirmation by raters, the mean age was 15.4 years (range 7–17, 
95% confidence interval [CI] 15.0–18.8) and 53.8% were males. The majority had a 
predisposition to psychiatric disorders (85.8%) and approximately one-third had a 
predisposition to a psychotic disorder. With regard to developmental problems in 
childhood, difficulties with social development and interactions was the most 
common, affecting one-third of the sample. Most patients had indicators of emotional 
or behavioral problems prior to the diagnosis of schizophrenia (85.7%), exemplified 
by self-harm, suicidal ideation and attempts, aggressive behavior, substance use and 
criminal behavior.  
1st step:  
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Maybe 
(n: 42, 23.6%) 
Incorrect 
(n: 25, 14.0%) 
Correct 
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Incorrect 
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Likely  
incorrect  
(n: 19, 10.7%) 
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(n: 23, 12.9%) 
Correct 
(n: 111, 62.4%) 
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(n: 134, 75.3%) 
Not confirmed schizophrenia  
(n: 44, 24.7%) 
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Of patients with information about childhood adversities, almost half had experienced 
trauma (46.9%), either violence, sexual abuse or assault, or other traumatic 
occurrences, such as, for example, having escaped from war, witnessing violent 
deaths. Stressful or adverse life events such as change of school, being the victim of 
bullying, parental death, parental separation and parental substance use were also 
common, with 93.1% having experienced one or more (Table 1). 
Table 1: Demography and prior history of confirmed cases (N = 132) 
Variables 
Number 
of records 
with data 
n (%) 
Male sex 132 71 (53.8) 
Developmental problems with 93 40 (43.0) 
- Speech and language development 93 16 (17.2) 
- Social development 92 31 (33.7) 
- Psychomotor development 95 10 (10.5) 
Predispositions, any 120 103 (85.8) 
 - Schizophrenia spectrum 109 43 (39.5) 
 - Affective spectrum 112 58 (50.9) 
 - Anxiety disorders 110 25 (22.7) 
 - Other disorders 116 53 (45.7) 
Adversities, any 130 121 (93.1) 
   Traumatic experiences  (violence, sexual or other) 98 46 (46.9) 
   Change of school 115 82 (71.3) 
   Parental separation 124 64 (51.6) 
   Parental death 123 12 (9.8) 
   Parental substance disorder 108 30 (27.8) 
   Other adversities 120 85 (70.8) 
Prior interventions or assessments outside psychiatry 117 97 (82.9) 
Prior indicators for problems 126 108 (85.7) 
   Self-harm 92 46 (50.0) 
   Suicidal ideation 118 70 (59.3) 
   Suicide attempts 118 28 (23.7) 
   Aggressive behavior  109 39 (35.8) 
   Criminal behavior 114 15 (13.2) 
   Substance use 130 35 (26.9) 
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Assessment of confirmed cases* 
Assessment with a semi-structured diagnostic interview was conducted in the clinic 
with 58 patients (52.7%), mostly using PSE/SCAN (41.8%)97,98. The vast majority 
had undergone somatic screening (n=125, 96.8%) and 95 (78.5%) were assessed using 
psychological tests of cognition. Insidious onset was most common and seen in 121 
patients (93.8%). Functional decline or problems with self-care were described in 118 
records (96.7%).   
 
VERY EARLY ONSET SCHIZOPHRENIA  
Few patients were diagnosed before the age of 13 (n=39) and only 35 records could 
be retrieved (89.7%).  
More registration errors were present in VEOS compared to diagnoses at an older age 
(n=6, 17.1%), yielding a concordance between DPCRR schizophrenia and clinical 
schizophrenia of 82.9% vs. 90.2% in patients diagnosed at the age of 13–17 years. 
These registration errors affected the validity of DPCRR VEOS which was 71.4% 
compared to 76.2% in the older patients.  
In the records with clinical schizophrenia, the validity of VEOS compared to 
adolescent onset did not differ.  
Since the sample of confirmed VEOS diagnoses consisted of only 24 patients, very 
few statistically significant differences emerged between VEOS and schizophrenia 
diagnosed between 13 and 17 years of age when looking at premorbid history and 
clinical characteristics. A prior history of self-harm, suicidal ideation and substance 
abuse were all more common in patients with a later onset (all p <0.05). There were 
tendencies which did not reach statistical significance for the following being more 
common in VEOS: male sex (70.8% vs. 50%), developmental problems (57.9% vs. 
39.2%), aggressive behavior prior to diagnosis (52.6% vs. 32.2%), traumatic 
experiences (55% vs. 44.9%), and familial psychiatric predisposition (95% vs. 85%), 
especially for psychotic disorders (50% vs. 37.4%) and other disorders (62.2% vs. 
42.3%).  
 
                                                          
* The results are based on the number of records with available information on assessment.   
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STUDY 3: LONG-TERM OUTCOME OF EOS  
Sample 
In study 3, we included 16,337 patients registered with a first-time schizophrenia 
diagnosis between 1996 and 2012, with 1223 (7.5%) classified as EOS. Mean ± SD 
age of onset among for the EOS group was 16.1 ± 1.7 years and 27.7 ± 6.3 years 
among patients with AOS. Mean ± SD follow-up was 9.5 ± 5.0 years (EOS 8.5 ± 4.5 
years, AOS 9.6 ± 5.0 years; p <0.001). The majority of the sample had reached 
adulthood at the end of follow-up, with only 77 patients in the EOS group below the 
age of 18.  
Primary outcome 
Being in the EOS group was associated with an increased number of inpatient days in 
the short-term, defined as the first 2 years with schizophrenia (incidence rate ratio 
[IRR] 1.44, 95% CI 1.33–1.57; p <0.001). For the remaining period, mean annual 
inpatient days were similar for EOS and AOS (IRR 1.07, 95% CI 0.90–1.28; p=0.46). 
Sensitivity analyses were conducted on four different subgroups, which confirmed the 
pattern in three analyses: the youngest-onset group had more inpatient days in short-
term outcome (p <0.005), with no differences shown in mean annual inpatient days in 
long-term follow-up. The exception was the sensitivity analysis comparing patients 
with AOS diagnosed at 18 years of age with those diagnosed with AOS at an older 
age, which found no difference in short-term outcome but more inpatient days in the 
remaining period for young adults.   
Moderators of primary outcome 
Comorbid substance use disorders were consistently associated with more inpatient 
days, both in the first 2 years (IRR 1.15, 95% CI 1.10–1.20; p <0.001) and in long-
term follow-up (IRR 1.70, 95% CI 1.57–1.84). The sensitivity analyses confirmed the 
finding with the exception of short-term outcome in the analysis within the EOS 
group.  Out-of-home placement during childhood showed the same pattern with 
increased inpatient days in both short-term (IRR 1.14, 95% CI 1.08–1.19; p <0.001) 
and long-term follow-up (IRR 1.32, 95% CI 1.22–1.44; p <0.001), this was also 
confirmed in the sensitivity analyses, with the exception of the sensitivity analyses 
including only patients with EOS.  
The findings on sex were diverse; in the short-term outcome there was no effect of 
sex on inpatient days (IRR 1.04, 95% CI 0.94-0.95; p=0.086), whereas male sex were 
associated with an increased number of inpatient days during long-term follow-up 
(IRR 1.09, 95% CI 1.00-1.18; p=0.041). In the sensitivity analyses, there was no effect 
of sex in either short- or long-term outcome, except for two analyses showing a very 
small difference. In the EOS group, male sex was associated with a decreased number 
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of inpatient days in short-term outcome (0.75, 95% CI 0.67–0.84; p <0.001) and no 
effect on long-term outcome (1.01, 95% CI 0.78–1.32; p=0.95).  
Secondary outcomes 
Most outcomes related to psychiatric admissions were similar between patients with 
EOS and AOS (readmission rates, mean annual number of admissions, length of stay 
and heavy use of inpatient days and mean annual number of involuntary admissions), 
but patients with EOS were less likely to never be admitted during follow-up (17.2% 
vs. 20.1%; p=0.012), had a longer first admission (87.4 days vs. 74.6 days; p=0.005) 
and more patients with EOS had been involuntarily admitted or hospitalized (41.0% 
vs. 36.0%; p=0.002). More patients with AOS were diagnosed with substance use 
disorder (34.2% vs. 21.7%; p<0.001). For outcome related to functioning, there was 
no difference in institutionalization in the last year of follow-up (3.4% in AOS, 2.9% 
in EOS; p=0.49), but patients with AOS had completed a higher level of education 
(20.4% EOS vs. 42.1% in AOS; p<0.001), whereas more patients with AOS were 
living on social benefits as their primary income source (75.7% in EOS vs. 83.2% in 
AOS; p <0.001).  
 
COMPARISONS WITH CONTROLS 
Patients and controls differed on almost all measures concerning demography, prior 
history and outcome measures. Patients had more parental predisposition (26.3% vs. 
12.4%; p<0.001), experienced more childhood adversities (all adversities; p <0.001), 
were more likely to have had prior psychiatric disorders and admissions (p <0.001), 
and their parents were less likely to be educated above law-mandated school level 
(65.3% vs. 71.5%; p <0.001), see Table 2. 
At the end of follow-up, <3% of the control group had been admitted to a psychiatric 
hospital versus 80% among the patients, controls were less likely to be diagnosed with 
a substance use disorder (1.3% vs. 33.2%; p<0.001), less likely to institutionalized 
during last year of follow-up (0.2% vs. 3.3%; p <0.001). Controls had completed 
education above law-mandated school more often (79.9% vs. 40.9%; p <0.001) and 
were more likely to be in unsupported employment (80.6% vs. 15.6%; p <0.001).  
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Table 2: Demographic presentation of cases and population controls 
Variable 
AOS 
(n: 15114) 
EOS 
(n: 1223) 
p-value 
Population 
Control 
(n: 49011) 1 
# male sex (N, %) 9557 (63.2) 602 (49.2) <.001 30477 (62.2) 
Age at onset (Mean years, SD) 27.7 (6.3) 16.1 (1.7) <.001 -  
Age at first psychiatric contact  (Mean 
years SD) 
24.9 (6.7) 15.0 (2.6) <.001 25.9 (9.8) 4 
# Any parental predispositions (N, %) 3194 (26.2) 341 (27.9) 0.196 4992 (12.4)*** 
# Predisposition psychotic disorder 
(N, %) 
760 (6.2) 71 (5.8) 0.62 647 (1.6)*** 
# Predisposition affective disorder 
(N, %) 
1326 (10.9) 122 (10.0 0.36 2154 (5.4)*** 
# Predisposition substance disorder 
(N, %) 
1022 (8.4) 103 (8.4) 0.96 1307 (3.2)*** 
# Predisposition other disorder (N, %) 2343 (19.2) 269 (22.0) 0.021 3465 (8.6)*** 
# Parental education above law-
mandated school, any 2 (N, %) 
8564 (64.2) 941 (78.5) <.001 
34496 
(71.5)*** 
Childhood adversities3     
# Out-of-home care (N, %) 2913 (19.4) 263 (21.5) 0.072 1272 (4.7)*** 
# Parental death, any (N, %) 613 (4.1) 44 (3.6) 0.43 1335 (2.7)*** 
# Divorce (N, %) 1633 (56.8) 509 (53.6) 0.083 4425 (38.6)*** 
# Parent incarceration (N, %) 759 (12.7) 143 (11.9) 0.45 1307 (6.1)*** 
# Parental psychiatric admission  
(N, %) 
1510 (12.4) 129 (10.6) 0.067 1942 (4.8)*** 
# Parent somatic admission >2 weeks   
(N, %) 
1251 (16.0) 177 (14.5) 0.18 3469 (12.8)*** 
# Previous disorder, any (patient) 
 (N, %) 
10649 (70.5) 808 (66.1) .001 2432 (5.0)*** 
# Premorbid psychotic disorder  
(N, %) 
4620 (30.6) 372 (30.4) 0.91 110 (0.2)*** 
# Premorbid affective disorder (N, %) 2630 (17.4) 185 (15.1) 0.043 447 (0.9)*** 
# Premorbid substance use disorder 
(N, %) 
3274 (21.7) 74 (6.1) <.001 359 (0.7)*** 
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.. table continued from previous page 
Variable 
AOS 
(n: 15114) 
EOS 
(n: 1223) 
p-value 
Population 
Control 
(n: 49011) 1 
 
# Premorbid other disorder (N, %) 7307 (48.4) 556 (45.5) 0.052 2093 (4.3)*** 
# Psychiatry prior to age 18 (N, %) 1828 (12.1) 1223(100) <.001 1081 (2.2)*** 
Admissions and prior inpatient days prior 
 to schizophrenia contact 
# No inpatient admissions prior  
(N, %) 
6793 (45.0) 757 (61.9) <0.001 
47962 
(97.8)*** 
 
 
 
(97.9)*** 
 
Inpatient days (Mean, SD)5 
141.5 
(253.4) 
99.0 (125.3) <0.001 -  
Inpatient admissions (Mean, SD)5 3.0 (4.0) 1.9 (2.6) <.001 -  
EOS: early-onset schizophrenia; AOS: adult-onset schizophrenia; SD: standard deviation 
1: P-value for difference between schizophrenia cases and population controls, with *= p<0.05, **= 
p=<0.005 and ***=p <0.001. 2: Parent with education above law-mandated school.  Data from 1940s. Only 
patients with available data are included. 3 Childhood adversities: Registers were initiated at different times. 
Only patients born after initiation of the registers were included in these analyses: Parental psychiatric 
history: From 1969. Out-of-home care: 1977. Separation: 1986. Incarceration: 1980. Psychiatric hospital 
inpatient: 1969. Somatic hospital: 1977. 4: Restricted to population controls with a psychiatric contact (n: 
4949, 10.1%). 5: Restricted to patients with prior admissions.  
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CHAPTER 4: DISCUSSION 
OUTCOMES OF EOS, WHAT DO WE KNOW 
Outcome of EOS was investigated in studies 1 and 3 from two different angles: a 
systematic literature-review using quantitative analyses and a register-based study of 
the full Danish EOS cohort compared to AOS.  
In our review of outcome of EOS (study 1), we included 21 studies from English 
journals published between 1986 until 2010, totaling 716 patients. Good outcome was 
found in 17.2% of the full sample, moderate in 28.2% and poor outcome in 54.6%. 
The proportion with poor outcomes were higher for studies only including patients 
with EOS compared to studies including both EOS and other EOP (EOS = 15.4% 
good, 24.5% moderate, 60.1% poor vs. mixed psychotic disorders = 19.6% good, 
33.6% moderate and 46.8% poor, p<0.001). Furthermore, the review described worse 
outcome for males, and a tendency for better outcomes in more recent time-periods. 
The review did not include studies on AOS, but compared to meta-analyses of AOS, 
we concluded that EOS carried a particular poor outcome.  
By using Danish, nationwide registers we were able to conduct study 3 with 1,223 
patients with EOS diagnosed between 1996 and 2012. Follow-up data was available 
for a mean of 8.5 years (SD 4.5, range 2-19 years) with almost no loss to follow-up. 
For comparison, an AOS sample of 15,114 patients diagnosed between 18 and 40 
years of age during the same time period were added as well as a control sample from 
the general population. The register data allowed for comparison of EOS and AOS 
within the same study design and from the same general population, but still with the 
limitation of treatment in different settings (child and adolescent psychiatry vs. adult 
psychiatry). Number of inpatient days was the primary outcome in study 3, 
investigating both short- and long-term outcome. Short-term outcome of two years 
are used in many studies of schizophrenia outcomes 151-161. Long-term prognosis is 
not always clear during the initial course 161, and to account for this we chose to treat 
the initial 2 years after diagnosis different from the long-term outcome. Inpatient days 
and admissions are universally understood as one way of measuring the severity of a 
mental disorder and important for administration and service planners as inpatient 
stays are an expensive part of treatment of mental disorders162.  Patients with EOS had 
worse short-term outcome with more inpatients days, but the EOS and AOS groups 
were alike in long-term outcome after two years. Patients with EOS had longer first 
admission, were more likely to be involuntary admitted and less likely to never be 
admitted. The two groups were alike on readmission rates, annual number of 
admissions and involuntary admissions, heavy use of inpatient days and 
institutionalization. The AOS group had more substance use and were less likely to 
be in education at end of follow-up, but had accomplished a higher level of education 
than the EOS group.  
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Our readmission rate of 77% in patients with EOS diagnosed during inpatient 
admission, were similar to findings by Thomsen83, who reported readmission rates of 
66% in the first year of follow-up and 80% after two years.  
We could not confirm more frequent, longer hospitalization and more relapses in 
patients with EOS in contrast to Immonen, but the differences described in the meta-
analysis all had low effect sizes (Rosenthal’s r between 0.11-0.17).  
Substance use disorders and out-of-home care were the most consistent predictors of 
inpatient days across analyses in both short- and long-term outcome. Other studies 
have showed associations between substance use and relapses and worsening of 
psychotic symptoms in patients with psychotic disorders163-167, and a frequent use of 
cannabis, especially of high potency, have also been found to trigger earlier onset of 
psychosis168. Study 3 found substance use disorders in 21.7% of patients with AOS 
and 6.1% with EOS were lower than other studies – an older review of psychotic 
disorders described cannabis use in 17-80% and alcohol in 21-86%169; a Scandinavian 
study found problems with alcohol and/or drug use problems in 33% 170, studies of a 
study of EOP reported cannabis use in 29% of the patients 171,  another EOP study 
14.6% for alcohol abuse and 32.1% for drug abuse27; an early detection program of 
FEP described drug-use in 17% of patients with EOP and in 28% of the patients with 
AOP50, and finally, a review of EOP reported substance use disorders in 32% at 
baseline  57. These numbers are more in line with our findings from study 2 where a 
history of illegal substance use was described in 33% of the patients with adolescent 
onset and 8% of the patients with VEOS. The lower numbers in study 3 might be 
explained by the use of register-based disorders instead of self-reports or interviews 
as register-based diagnoses for substance use disorders have been shown to have high 
specificity, but low sensitivity 172. In contrast to most findings, including ours, a recent 
study by Rylander et al. found cannabis use to be associated with shorter inpatient 
stays and to have no difference with regard to 30-day re-admission rates 173, but only 
20% of patients in the study had schizophrenia.  
In Study 3, data concerning substance use during follow-up were calculated for the 
EOS and AOS group with descriptive analyses, using chi square to determine 
percentage of patients having had this outcome. The disadvantage of this method was 
leaving out the differences in length of follow-up between the groups as in the groups 
and thereby differences in time at risk. However, for substance use, such a method 
would also have some potential biases; 21.7% of the AOS population already had 
substance use by the time of diagnosis and thereby would be in greater risk from the 
outset, while the youngest in the EOS sample might not be in risk for substance use 
disorders from time of diagnosis.  
Childhood adversities 
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The other covariate which were associated with inpatient days in most of our analyses 
was out-of-home placement during childhood prior to schizophrenia. Out-of-home 
placement is a by-proxy measure of childhood adversities which is a broad concept 
used to describe a wide range of difficult circumstances and experiences during 
childhood and adolescence. It can include severe trauma, violence, neglect, sexual 
assault, loss of or separation from parents, and being the victim of bullying, among 
others.  
Placement out-of-home does not only constitute an adversity due to the separation 
from parents, but are also based on prior adversities. Whether voluntarily or with the 
parents’ acceptance, placement of a child in foster care or an institution will only 
happen as a result of the child having grave behavioral or emotional difficulties, or 
special circumstances in the families, such as lack of basic parenting skills, substance 
abuse, neglect or severe mental disorders. A Danish study found children of mothers 
with schizophrenia to have a 40% risk of being placed in out-of-home care117. In study 
3, 20% of the patients had previously been placed in out-of-home-care during 
childhood, which was four times more than the control sample. Furthermore, we found 
hospitalization to be increased in patients who had been placed in out-of-home care, 
even in long-term outcome. This could possibly be explained by a reduced social 
network, as well as reduced coping skills, including the ability to effective emotion 
regulation, an ability associated with stable childhood and secure attachment174,175. 
Furthermore, there is evidence that the involvement of family members has a positive 
effects on prognosis 176, and many children and adolescents placed in out-of-home 
care do not have the opportunity to benefit from healthy family involvement in their 
recovery. 
Research of childhood adversities has increased significantly in the past decade177, 
with several meta-analysis presenting consistent findings of high rates of adversities 
in patients with psychoses 178-181, in line with our findings from study 2. In a meta-
analysis including studies published between 1980 and 2011, Varese et al. reported a 
significant association between childhood adversities and psychotic disorders; this 
association was not seen for parental death, but for both psychological, physical and 
sexual abuse, emotional and physical neglect and bullying (OR 2.4–3.4)181. Based on 
descriptions in the psychiatric records, we found that 47% of the patients with EOS 
had traumatic experiences and 93% had experienced adversities, also including more 
common experiences such as separation and school change.  
Our finding in study 3 of a doubling of childhood adversities in patients compared to 
the experiences in the general population (placement in out-of-home care, parental 
incarceration and parental psychiatric admission)  is in line with other studies: In an 
Australian study, 30% of patients with psychotic disorders had adverse experiences in 
childhood versus 15% in the general population 180, whereas a Danish study of early 
intervention in schizophrenias (OPUS) found 89% of the patients to have experienced 
childhood adversities compared to 37% in the matched control group182.  
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Until recently, the etiological role of 
adversities in the development of 
psychoses has been unclear183, but the 
evidence of a causal role at least for some 
people with psychotic disorders is 
growing strong177,184,185. Stilo et al. argue 
that the association between trauma and 
psychoses meets the the Bradford Hill 
criteria186 regarding causation with the 
exception of specificity185, see Table 3 
for the full Bradford Hill criteria. 
Specificity is not met as childhood 
adversities increases the risk of several 
mental disorders and not just 
schizophrenia – other register studies 
have found childhood adversities to 
increase risk of, e.g., ADHD187 and 
affective disorders. Childhood 
adversities seem to both increase risk of 
development of psychoses177,184 and the 
outcome184. In our register study of 
inpatient days (study 3), out-of-home 
placement was considerably more 
common in the patients than in controls 
and also highly associated with inpatient treatment with regard to short-term and 
especially long-term outcome.  
 
Outcomes related to functioning 
In study 3, we presented three outcome measures related to functioning at end of 
follow-up: institutionalization, primary source of income and having completed 
education past law-mandated school. Such measures are important in assessing 
outcome in patients with schizophrenia, as patients with remission in symptomatic 
outcome are still often struggling with impairments in social and vocational 
functioning, first reported in detail by Karow et al.’s studies188. Functional and 
symptomatic remission are often related, and better vocational outcome has been 
associated with higher rates of symptomatic remission and recovery and lower rates 
of relapse as well as a higher quality of life189.   
In the group of patients with AOS; 42% had completed an education above law-
mandated school versus only 20.4% among the EOS patients. Both numbers were low 
- Strength: Strong associations are more 
likely to be causal than weak associations 
- Consistency: If the same results can be 
found prospectively, retrospectively and 
in different populations 
- Specificity: The case for a causal 
explanation is strengthened if an 
association is only found in specific 
groups with the same exposure 
- Temporality: Necessary criterion that 
exposure most precede outcome 
- Biological gradient: A causal association 
is more likely if a dose-response curve 
exist. 
- Plausibility: A causal association is easier 
to adapt and believe if it seems plausible. 
However, Bradford Hill noted that this 
would depend on the current knowledge 
of biology. 
- Experiment: If interventions or 
preventive actions can alter the frequency 
of the outcome, it gives strong support to 
a causation.  
- Analogy: Analogies may add to evidence 
of associations otherwise weak.  
Table 3: Bradford Hill criteria186,220 
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compared to the control group drawn from the general population, in which 79.9% 
had completed education, with slightly more in the younger group.  
During the last year of follow-up, 3.3% of the patients had been living in an institution 
compared to 0.2% in the population controls. No difference between patients with 
EOS and AOS appeared. This number is lower than other studies of 
institutionalization among patients with schizophrenia39,190: In the ISoS study, 11.6% 
of the patients from the schizophrenia incidence cohort had spent the majority of the 
past 2 years in institutional settings at end of the 15-25 years follow-up39. Uggerby et 
al. included patients diagnosed with schizophrenia since 1969 and found 9.8% to be 
institutionalized in the year of 2006190. The OPUS-trial have reported proportion of 
institutionalization of 5-13% at different points of follow-up 191,192. The reason for 
lower rates in our study is not clear.  For older studies, such as the ISoS study, it may 
be explained by the aforementioned de-institutionalization. Also, compared to the 
ISoS study, we did not count hospitalization as institutionalization but reported both 
individually. The difference between our findings and the OPUS-trial may be based 
on selection, regional differences of use of institutionalization or time period of 
diagnosis – the OPUS-trial included 547 patients diagnosed in Copenhagen or Aarhus 
from 1998–2010, whereas study 3 included 16,337 patients diagnosed in all of 
Denmark between 1996 and 2012. In Uggerby et al’s sample, their study selection 
included patients diagnosed since 1969 which may be part of the explanation for the 
different rates found. It was not explored in the design of study 3, if institutionalization 
in long-term follow-up differed with time of diagnosis.  
In contrast to the meta-analysis by Immonen, our study could not confirm a generally 
poorer occupational functioning of EOS, with the exception of level of education48. A 
high number of patients in both groups were depending on public benefits at end of 
follow-up (EOS 75.7%, AOS = 83.2%), while only 16.4% were dependent on social 
benefits in the matched control group. These findings of dependence on social benefits 
and less than 20% employed in unsupported work are in line with other studies on 
FEP: in the AESOP-10 study of patients with FEP, only 22% of the patients were in 
paid employment at the ten year follow-up193; White et al. reported proportions of 
19% in paid work194, Jarbin and Hansson reported 89% in an EOS sample to be on 
disability at the 10 year follow-up195, and in the Danish OPUS-study, functional 
recovery was met for 14% of the sample at the 10 year follow-up (n=304), defined ad 
engaged in work or study, GAF-F >60 at no psychiatric hospitalizations or living in 
supported accommodation for two years196.  
Some studies on schizophrenia have found more positive employment outcomes: The 
ISoS study with 502 patients with incident schizophrenia reported 37% to be in paid 
work and 20% to be engaged in relevant housework at end of follow-up, 15-25 years 
after diagnosis39. Interestingly, compared to our study, the ISoS had a higher 
proportion of patients institutionalized at end of follow-up, while at the same time the 
rate for employment in ISoS was almost doubled compared to the Danish register-
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based findings39 This difference is likely explained by difference in sample selection 
– the ISoS study included patients from 14 incident samples from very cultural diverse 
settings whereas all the patients in study 3 are patient diagnosed and treated in 
Denmark. It is thus possible that the higher rates of paid work in the ISoS may partly 
be owing to some societies with less opportunity for receiving social benefits than the 
Danish society. The authors of the ISoS findings underline that the variations across 
centers were wide 39. However, findings from the EPPIC study are also more 
promising with regards to vocational outcome: at 7 year follow-up, 58.5% in the EOP 
group and 41.8% in the AOP group were either employed or studying, and another 
paper from reported full social and vocational recovery in 25% at the 7.5 year follow-
up197, including adequate interpersonal relationships and vocational functioning, 
measured by the Quality of Life Scale (QLS)198. 
Outcome of VEOS 
Separate analyses of patients with VEOS cases were planned, both in studies 2 and 3. 
Only 39 patients with VEOS were registered in the period for study 2 (1996–2009), 
and only 52 in the period for study 3 (1996–2012). Study 2 found VEOS in the 
DPCRR had a higher rate of registration errors than schizophrenia diagnosed in 
adolescence (six of 35 collected records, 17.1% vs. 9.8% in the adolescent sample). 
Statistical analyses of the selected VEOS group in study 3 was therefore not conducted 
owing to risk of false findings. In Study 2, we compared the 24 confirmed VEOS 
cases with the 108 confirmed cases with onset in adolescence, but few statistic 
significant findings emerged, likely due to sample size. Comparing adolescent onset 
and VEOS, only three indicators of problems prior to diagnosis reached statistical 
significance – all more common in adolescent onset: self-harm (56.3%& vs. 28.6%), 
suicidal ideation (65.3% vs. 30%), and substance use (31.1% vs. 8.3%). Premorbid 
difficulties, higher genetic load and a predominance of males have been described in 
other VEOS studies 21,83. These characteristics were all present in the VEOS sample 
in study 2 in higher numbers than in the group of patients diagnosed in adolescence, 
but did not reach statistical significant levels, likely owing to the low number of VEOS 
patients (n=24 confirmed cases).  
The low prevalence of VEOS, underscores the importance of a longitudinal study like 
NIMH-COS, including patients from a large geographical area to study this group of 
patients.  
Summarizing the findings of outcome:  
Similar to the meta-analysis by Immonen et al.48 including both early and adult onset, 
the majority of outcomes investigated did not differ between early- and adult-onset in 
study 3. This conclusion is in line with findings from other studies 199. Two studies 
from EPPIC including 366 patients with first-episode psychotic disorders and a 
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follow-up of approximately 7 years. Although the number of EOS and EOP patients 
were fairly low (n= 20 and 41, respectively), a significant difference between early- 
and adult-onset was found on several scales of psychopathology, functioning, 
occupation and quality of life, with patients with early-onset presenting with the most 
favorable outcomes in this study199. The AESOP study indirectly lends support to 
these findings: Lappin and colleagues compared 10 year outcomes of patients with 
non-affective psychoses and compared groups with different age cut-offs200. The 
outcome was similar for the groups diagnosed prior to or after age 25 as well as prior 
to or later than 35200, leading to a recommendation that early intervention should not 
be restricted to certain age groups.   
Based on the findings from study 3 as well as the current literature, I am in line with 
Immonen et al. in concluding that age of onset is not as important for outcome as 
previously thought48. 
 
VALIDATION STUDIES: DESIGNS AND CRITIQUE 
In study 2, findings from a validation study of schizophrenia diagnoses in children 
and adolescents in the DPCRR were presented. Psychiatric records from 200 patients 
with EOS were randomly selected in the DPCRR, 178 could be retrieved (89%) and 
were all rated by two experienced clinicians. Of the retrieved records, 10.2% were 
registration errors in which the DPCRR schizophrenia diagnosis did not match the 
clinical diagnosis described in the records. The validity of the DPCRR schizophrenia 
was 75.3% for narrow schizophrenia and 83.7% for schizophrenia spectrum disorders. 
Of the 158 records with a clinical schizophrenia diagnosis, the raters confirmed 83.5% 
as schizophrenia and 91.8% as in the schizophrenia spectrum.  
To my knowledge and in accordance with Byrne’s review of validation studies from 
2005, no gold standard exist for validating register data70. Byrne included 14 
validation studies of register data published between 1966 and 2004; the results were 
briefly outlined in Chapter 1. Byrne and colleagues pointed out that most studies do 
not clearly define validity before analyzing their results70.  Instead, Byrne and 
colleagues listed important parameters for the evaluation of quality in validation 
studies. In Table 4 below, the validation study is assessed using these parameters. 
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Table 4: Validation methods compared to Byrne’s suggested standards70 
Standard Validation study of EOS 
Sample 
Diagnoses Only schizophrenia. No validity rating of comorbid diagnosis.  
Sample size 
described  
Yes (200 records, 178 collected) 
Randomization used 
and described 
Yes, all VEOS cases + random sample of EOS, matched by sex and 
geography to full sample 
Study sample 
description 
Yes (sex, age of onset and diagnosis, in- or outpatient setting, 
assessment in clinic, symptom distribution, duration, psychiatric 
predisposition, childhood characteristics and adversities) 
Representativeness 
of the sample 
described 
Yes. The register include close to all patients with schizophrenia in 
Denmark. The randomization make the study highly representative for 
patients with EOS in Denmark.  
Assessment 
Assessment 
method 
Yes (raters evaluated selected material from psychiatric records and 
used a pre-defined checklist with ICD-10 criteria). Concordance 
between clinical and register was assessed as well as validity of the 
clinical diagnosis according to raters.  
Triangulation of 
assessment 
No. Only psychiatric records were used. As patients were diagnosed 8-
20 years ago there would be both recall-bias and ethical considerations 
if they should be contacted.  
Methods 
Statistical analyses 
Simple calculations of agreement between register diagnosis and 
psychiatric records as well as agreement between both and raters' 
diagnoses.  
Blinding of 
diagnosis 
No. The raters knew that all cases were registered with a schizophrenia 
diagnosis in DPCRR  
Blinding of rater' 
evaluation 
Yes. Two raters evaluated all records, blind to each other's rating. In 
case of disagreement, diagnosis was discussed to reach consensus.  
Inter-rater reliability  Yes, by use of Cohen's kappa 
Diagnostic reference 
standard used 
Yes. All records were rated in accordance with ICD-10 criteria, using a 
check-list with all criteria described in detail.  
 
Using these quality measures, the validation study fulfills most criteria. The main 
limitation of the study is the inclusion of only one diagnosis. Thereby, blinding of 
raters to diagnosis was not possible and the decision yielded an indication bias where 
the agreement could be an overestimate, as all raters knew the register-based and 
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clinical diagnoses. Furthermore, false-negative rates could not be estimated.  It is 
likely that some children and adolescents are diagnosed with psychotic disorders in 
the DPCRR who, upon closer examination of the psychiatric records, would be 
reclassified as having schizophrenia. In a Finnish validation study of register 
diagnoses, including psychoses, personality disorders and substance abuse, 16% were 
false-negatives and met criteria for schizophrenia71, a Swedish study found 10% false 
negatives in a study of psychotic disorders 60, and Fennig et al. reported a 15% false-
negative diagnosis rate in a study comparing clinical and research diagnosis of 
psychotic disorders201. It is possible that the rate of false-negative diagnoses among 
other psychotic disorders in child and adolescent psychiatry would be even higher, as 
some clinicians may avoid or delay a diagnosis of schizophrenia in children and 
adolescents owing to either lack of experience or fear of the consequences of 
diagnostic labeling8, which could be stigma from their surroundings or even the risk 
of stifling the adolescent’s development as a result of the knowledge of having a 
serious mental disorder.  
By using only psychiatric records, the study is also potentially biased by the selective 
recording of the clinician involved in the assessment. As Byrne points out, there will 
be a tendency to highlight symptoms and findings that fit your hypothesis rather than 
characteristics which may elicit doubt70. To overcome this bias, record assessment 
would have to be complemented by interviews of patients or observations. In the 
current study, we did not consider this solution feasible as it would entail recall bias. 
The patients would have to remember symptoms described 7–20 years previously and 
may be affected by how their disorder later progressed. Contacting patients many 
years after their diagnosis would also raise ethical considerations, and, finally, such a 
study would likely have a high rate of patients refusing to participate.  
Our rating categorizations allowed a rating of ‘maybe’, which was then specified as 
‘likely correct’ or ‘likely incorrect’. As a third step, likely correct and correct were 
categorized as ‘confirmed’, and likely incorrect and incorrect as ‘not confirmed’. It is 
suboptimal to categorize diagnoses deemed only ‘likely correct’ as a confirmed 
diagnosis. With regard to the terms of the study, we believe the chosen categorization 
was the best compromise: with a retrospective validation study, we could not 
administer additional assessments; furthermore, for some records, we did not have 
access to the full psychiatric record. The fact that 34% of the unconfirmed cases met 
the criteria for schizophrenia spectrum disorders (e.g. schizoaffective disorder, 
unspecified psychoses) underlines that ‘likely correct’ was not used to excess.  
To some degree, this decision reflects real life in the clinics – sometimes the clinicians 
do not have access to all prior relevant data, the patient may refuse assessment, 
resources can be inadequate, or a patient might be seen at a time where the full 
symptomatic picture has not yet been developed; this stage can retrospectively be 
labeled prodromal schizophrenia. Finally, our classification systems are manmade to 
find similarities and differences between disorders and clusters, and guide us in 
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treatment choice. Changes in classifications and descriptions are made as more 
knowledge and evidence emerges. However, it is still just a system and not all will fit 
in the categories like shapes in a sorting cube.  
In order to identify potential validation studies published after Byrne et al.’s review, 
the same search terms were used for publications from 2004 and onwards but adding 
‘schizophrenia’ or ‘psychoses’ or ‘psychotic’ in the search. Additionally hand-search 
was conducted through inspection of references in other validation studies. One older 
studies not included in the original meta-analysis was found by hand-search: a study 
from Saskatchewan in Canada investigating the concordance between administrative 
hospital databases and psychiatric records, including 131 patients with schizophrenia 
in the register202. Rawson and colleagues reported diagnostic concordance of 77.1% 
using four-digit codes (schizophrenia subtypes) and 93.9% using three-digit codes. 
Furthermore, demographic and personal factors were accurate in more than 94%202. 
The diagnostic validity was not assessed, only concordance. 
Since 2004, only four new studies on the validity of schizophrenia or psychotic 
disorders in registers was found; one Danish and three Finnish studies62,63,203,204. In 
one study, the interviewer was blind to the diagnosis, the other studies did not use 
blinding of raters or assessed interrater-reliability. Sample descriptions included 
gender and age in all three studies, and Uggerby et al. also described the symptoms 
distribution in the sample. Arajärvi et al. investigated register diagnoses of 
schizophrenia in an isolate population born between 1940 and 1969 using both 
psychiatric records for consensus diagnosis as well as diagnostic interview204. 
Consensus ratings of records were conducted for 164 patients and 131 of them also 
participated in interviews. The concordance of patients diagnoses with schizophrenia 
in both register, rating of records and in psychiatric interview was 55%. Among the 
140 patients registered with a schizophrenia diagnosis in the register, 72.1% (n=101) 
was confirmed by ratings as schizophrenia, 87.9% (n=123) as in the schizophrenia 
spectrum and 97.1% (n=136) as disorders with psychosis.  
Finally, a Danish study by Pedersen et al. has investigated the accuracy of 
documentation of psychiatric care for patients with schizophrenia in the medical 
records, by assessing the accuracy between the Danish National Indicator Project for 
schizophrenia and the psychiatric records205. They were unable to locate 12.4% of the 
psychiatric records. The psychiatric records had varying levels of missing 
information. For assessment of psychopathology, 37.5% records had missing 
information, while the completeness of antipsychotic treatment was high, with only 
1% missing information.   
Although no gold standard exist for validation studies and the papers report their 
findings in different ways, most papers provided information regarding number of 
correct cases in the register (“true positives”). The number of confirmed cases by 
raters varied from 50% to 100% in the 16 studies: 3 studies confirmed 50-66%64,206,207, 
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5 studies (including ours) confirmed 72-78%61,63,69,204, 3 confirmed 82.9 – 
87.5%59,73,208, and finally 5 studies confirmed as many as 93.9 – 100%62,71,72,202,203 of 
the register-based diagnoses. With our number of 75.3% confirmation of register-
based schizophrenia and of 83.5% as in the schizophrenia spectrum, the validity of 
the DPCRR for EOS is in the mid to lower range compared to most register-studies 
of schizophrenia, but the result is almost identical to the one other study investigating 
validity of EOS – Dalman confirmed 76% of the register-diagnoses as schizophrenia 
and 86% as in the schizophrenia spectrum69 – indicating the EOS is a more difficult 
to diagnose accurately. The rate of registration errors were higher for EOS in DPCRR 
than described in the other studies. Removal of the registration errors, increased the 
validity in our study to 83.5% for schizophrenia and 91.8% for schizophrenia 
spectrum disorders.  
 
STRENGHTS AND LIMITATIONS 
In study 1, results from 21 studies were pooled and analyzed. To my understanding, 
our systematic review of EOS published in BMC Psychiatry in 20121 was the first 
review to use quantitative analyses to assess the outcome. However, heterogeneity 
was a challenge, as present in design of the 21 studies in terms of the diagnostic 
classification used (ICD-9, ICD-10, DSM-III, DSM-III-R, DSM-IV), outcome 
measures (global functioning scales, employment, social disability and living 
situation, course of the disorder), length of follow-up (2–42 years), retrospective or 
prospective and sampling. The challenge of heterogeneity has also been described in 
other meta-analyses of outcome26,57. 
In study 3 – using the full cohort of all patients in Denmark diagnosed with EOS in a 
certain period – many of the potential challenges and biases from comparing different 
study designs were eliminated. However, register-based studies over long periods still 
have bias in terms of changes in organizational structure such as the de-
institutionalization in psychiatry, and using calendar-year of diagnosis as a co-variate 
in the regression analyses was added to correct for this.  
Prospective cohort studies, as well as randomized controlled trials, are difficult to 
conduct in EOS owing to the low incidence and prevalence of the disorder resulting 
in small sample sizes. Long-term prospective studies are even harder to conduct, as 
larger samples are needed owing to high attrition rates in these studies. In study 1, the 
mean sample size was 44 (range 9 – 81 patients), and even in meta-analyses of EOS 
or EOP, the total number of patients is relatively low (n = 716 in our review of 21 
studies, n = 773 in Stentebjerg et al.’s review of 28 studies209). These methodological 
difficulties calls for research with other study designs to investigate the course and 
outcome of EOS.  
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By using the nationwide Danish registers, we were able to follow-up a cohort of 1,223 
patients with EOS and comparing them to a large group of patients with AOS in study 
3. To the best of our knowledge, this is the largest study to date of patients with EOS. 
The patients were followed for 2–19 years of follow-up, with a mean of 8.5 years in 
the EOS group.  
Register studies have an advantage in epidemiological research, as it is possible to 
perform large-scale studies with data that have already collected. In a country with 
free access to health care and no private psychiatric hospitals, register-based studies 
can be conducted with little selection bias. Schizophrenia studies and psychiatric 
research in general often have a high attrition rate (‘dropouts’), in studies of 
psychosocial treatment, pharmacological trials 210,211 and outcome studies 212. It is not 
clearly established if dropout is associated with a specific outcome. In our systematic 
review of 21 early-onset studies, (study 2), the median attrition rate was 28% and in 
three of the studies, it was > 50% 1. In the studies with a high number of dropouts, the 
outcome tended to be worse. This is in line with some other studies: an Indian study 
reported that > 60% of patients completely lost to follow-up had been in a state of 
remission when last seen 213, whereas another study described higher dropout rates in 
patients with a severe course214. Menezes et al., who described a reasonably favorable 
course in their meta-analysis of 4100 patients with first-episode AOP, suggested 
selection bias and attrition bias might be part of prior findings with a more severe 
prognosis. Patients in recovery or with good outcomes may be lost to follow-up37.  
By using registers to assess the outcome of schizophrenia, we could circumvent the 
bias of dropout. It is a great advantage of study 3 that there was virtually no loss to 
follow-up. With extensive registers for employment, housing, hospital treatment, 
education, medication, mortality and crime as is the case in Denmark and other Nordic 
countries, there is virtually no loss to follow-up. People will only leave the registers 
if they either leave the country or if they are not in contact with any public services, 
including social benefits, emergency rooms, healthcare etc. Since data are collected 
automatically, there should be no collection bias. Selection bias is reduced as all 
patients are included, thus not restricting to a certain geographic area or socio-
economic group. Some selection bias remain as our patient sample can only include 
patients who were in contact with the health system and diagnosed – this bias is also 
present in most clinical studies.  
 
LIMITATIONS BY REGISTER-BASED STUDIES 
Defining EOS and AOS by use of the registers is different from clinical studies. In 
clinical studies with assessment of patients or information from close relatives, age of 
onset is mostly defined as age of the first clear psychotic symptoms. This method is 
not possible in register research as there is no access to data in the psychiatric records 
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or from specific assessment instruments, and no contact with patients. The most 
commonly used method in register studies is index date (first day of first hospital 
contact with the diagnosis, either as an in- or outpatient)215,216. Another possible 
method in register-based studies would be to use first day of first antipsychotic 
treatment or first day in inpatient treatment, whichever comes first. However, some 
patients are treated with antipsychotic medication prior to true psychotic symptoms 
as a means to aid better sleep or less chaotic thinking.  
By using the index data as the time of onset, there will be large variations between the 
time of index date, the time of onset of first psychotic symptoms and the time the 
clinician decide on the diagnosis and to initiate treatment. Some patients have had 
psychotic symptoms over diagnostic threshold for years prior to seeking help, others 
present with high-risk symptoms which may later turn out to be prodromal, and still 
others seek help for depressive disorders, suicidal thoughts, anorexia, etc., where the 
disorders may progress to schizophrenia during the psychiatric course. In all 
probability – based on studies of DUP – age of onset defined by index date will be 
later than the age of onset defined by onset of psychotic symptoms. This corresponds 
to the findings in study 2, where estimated age of first psychotic symptoms were more 
than 1.5 years prior to the schizophrenia contact.  Quality research of the Danish 
assessment and treatment of schizophrenia has shown that DUP is > 6 months for 
approximately half of patients in both EOS and AOS86-88,217. It is therefore possible 
that part of the patients with AOS have had early-onset. In study 3, a sensitivity 
analyses was conducted, comparing patients with EOS to AOS patients diagnosed 
after the age of 25 to address this bias, and we confirmed the same findings as in the 
main analyses.  
Accuracy and coverage of register data are not always known which is another 
limitation of register studies. Compared to the extensiveness of register data, only a 
fraction of the data or even the data variables have been assessed. As described 
previously, most studies of diagnostic validity report adequate to high quality data, 
however most studies have not assessed the accuracy of all the other data reported to 
the register, such as dates for visits and comorbid disorders or quality of care205. 
Admission dates have been found to be reliable in register studies from other 
countries59,208, dates from visits to outpatient facilities are probably more uncertain208.  
Finally, register-based research have a challenge in the endless possibilities. Research 
should always be driven by hypothesis and not ‘data-fishing’. The magnitude of data 
in the registers are so large that almost anything will be able to elicit a result, with p-
values pointing to a true difference. Furthermore, as with clinical studies, researchers 
should always be wary of statistical differences that may point to a true difference 
with regard to p-value but where the effect, power or numerical relevant is so low that 
it is clinically irrelevant. With regard to the secondary outcomes of study 3, we found 
some outcomes to be different between EOS and AOS but with a fairly small 
difference. Five percent more patients with EOS had been involuntary admitted, and 
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3% fewer patients with EOS had never been admitted, whereas other outcomes were 
more convincing of a clinically relevant difference – e.g. half as many patients with 
EOS as those with AOS had completed above law-mandated education and 13% more 
patients with AOS were diagnosed with substance use disorders. Those are the 
differences that we should attempt to address through targeted interventions.   
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CHAPTER 5: IMPLICATIONS FOR THE 
FIELD AND FUTURE RESEARCH 
Perspectives for clinical practice from the validation study 
For disorders with a likelihood of a long psychiatric course, it is desirable to be able 
to go back and evaluate the premise of the diagnosis for the first episode. Even in 
records where we had access to all material from the original assessment, the raters 
were sometimes in doubt due to vague clinical descriptions. 
Our findings suggest that clinical practice can be improved concerning descriptions, 
as it was sometimes not possible to decide whether the symptom reached a clinical 
threshold (e.g. no impact/distress; very short duration; only happened 1–2 times). 
Some descriptions would be as short as ‘patient has bizarre delusions’, which is 
insufficient, especially given the fact that clinicians are not always in agreement with 
regard to definitions of ‘bizarre’. Furthermore, it was not always clear if potential 
differential diagnoses had been considered.  
In Chapter 4, the role of trauma in psychosis was discussed, highlighting the findings 
from studies 2 and 3, both pointing to a high number of patients having experienced 
trauma or adversities as also known from other studies. While the presence of trauma 
is not necessary for a schizophrenia diagnosis, trauma and adverse events are 
important for future treatment planning and understanding the individual patient 
where traumatic experiences from the past may influence the specific delusions or 
hallucinations, as well as reduce the coping abilities of the patient. The subject of 
trauma should be addressed at an appropriate time during the assessment phase. The 
presence of psychopathology does not influence the likelihood of reporting abuse, and 
reports are fairly consistent over time, also in patients with psychotic disorders, and 
underreporting of trauma is more probable than false accounts218. The patient may not 
be ready to talk about it at this point, but by addressing the issue, the clinician conveys 
that this is a subject that can be talked about. Studies have found that clinicians often 
either do not ask about trauma or do not document if a trauma history have been 
taken218,219. This tendency were also seen in study 2 where patients and caregivers 
were often not asked about traumatic or stressful events in the initial assessments, and 
in >25% of the records, I could not find any descriptions of trauma or adversities being 
considered. 
Finally, we discovered what seems to be a systematic bias in the outpatient 
schizophrenia diagnoses in the DPCRR: of the 79 schizophrenia diagnosed given in 
outpatient settings, 15 were misclassifications (19%) and the majority of these were 
owing to the same type of error: The patient was seen in the outpatient clinic, a 
suspicion of schizophrenia emerged and the patient was referred to an inpatient facility 
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for further treatment. A final diagnosis of schizophrenia had not been made, yet the 
outpatient contact was coded as such. This systematic error could be eliminated by 
coding a psychiatric contact as unspecified psychosis (F29 in ICD-10) as long as the 
assessment for schizophrenia is still ongoing.  
 
Implications for register studies:  
Based on our finding of higher validity of inpatient schizophrenia diagnoses, future 
register studies of EOS could restrict their sample to patients diagnosed as inpatients. 
However, such restrictions would also depend on the nature of the study as an 
exclusion of patients with no admissions would exclude some of the patients with the 
best prognosis. Another way to limit the risk of registration errors would be to require 
at least two contacts with schizophrenia. In study 3, we chose to conduct sensitivity 
analyses with different subgroups of the sample and in this way confirmed the overall 
findings without biasing towards a more severe sample.  
 
Proposition: Systematic and frequent validation studies 
Denmark has a valuable research source in its registers, but to uphold the scientific 
value of the registers, the data must be of high quality regarding both concordance 
and clinical quality in classification.  
Far from all psychiatric diagnoses in the DPCRR have been through quality assurance 
in terms of validity and concordance studies, and some diagnoses have mostly or only 
been investigated in adults or children/adolescents (attention-deficit hyperactivity 
disorder, autism). McConville and Walker investigated the reliability of diagnoses in 
Scotland’s psychiatric register and found varying reliability and frequency of 
misclassifications across the diagnoses207. On the basis of their study, McConville and 
Walker recommended investigations of all diagnoses individually in terms of 
reliability207. I agree with this conclusion and would suggest a more organized 
structure of frequent and systematic validation studies of diagnoses in the DPCRR.  
Systematic and frequent validation studies of all major mental disorders would benefit 
the clinicians in Danish child, adolescents and adult psychiatry. Furthermore, it would 
be valuable for psychiatric research due to the many register studies coming from 
Denmark. Today, all psychiatric departments have electronic patient records, which 
would make the study process much easier than studies conducted in time periods 
with paper records (including study 2).  
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Such a step would require an organizational set-up. Currently, validation studies of 
register data are mostly conducted by researchers prior to a register-based study where 
an investigation of the data quality is needed. The validation study is thus designed to 
meet the specific requirements of the future register study. By continuing this path, 
some disorders may never be validated and others will only be validated for subgroups 
of people or for a certain period of time. By having a better organizational practice in 
place, studies could be designed with appropriate time intervals, with a design 
allowing comparisons between studies, and they could be designed to include 
registration errors, clinical as well as register-based validity, sensitivity and 
specificity. Furthermore, it would be possible to carry out the studies close to the time 
of diagnosis with the organizational structure in place; permissions and data collection 
procedures would be more efficient and the framework already laid out. Conducting 
register-based studies may seem like an easy process, but without an organizational 
structure, there are several logistic challenges and extensive data-management.  
As an added bonus, systematized validation studies would be beneficial for the 
training of younger doctors and psychologists, by offering a current update on 
diagnostic tendencies, administrative practice leading to registration errors etc.  
Last but not least, the patients: By continuously educating ourselves and maintaining 
high quality assessment, the chances are higher that the individual patients will receive 
the most correct assessment of his current state.  
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CHAPTER 6: WHAT DO WE TELL THE 
PATIENTS?  
After having studied the outcome of early onset schizophrenia – and owing to the 
research design of the project, also educated myself and others on the outcome of AOS 
in the process – I have often asked myself whether this would alter the way I answer 
questions from my patients.  
‘Will this pass?’ 
‘Do I have to take medication forever?’ 
‘Will she ever be able to take care of herself again?’ 
The questions are many, and the torment and despair often evident in the acute phase 
of the disorder. Once it passes, and the patients fare better, the fear of becoming 
psychotic again is often present.  
I entered research with to a desire to be able to answer these questions more in depth 
and confidently. I knew the common numbers; we as clinicians often tell our patients: 
‘20–25% have complete remission, 50% will have a moderate outcome with half 
having episodes but feeling well in between, and 25% will continue to experience 
psychotic symptoms’, but at the same time I knew that child and adolescent onset had 
a particularly poor prognosis. When I started the PhD project and gave my first poster 
presentation at a Danish conference, I had a therapy session with one of my regular 
patients scheduled shortly thereafter. My poster was right outside my office in the 
hallway – the poster highlighted all the findings from our review on the prognosis of 
EOS (study 1). In particular, the conclusion ‘In contrast to the adult manifestation, 
the early manifestation of schizophrenia in childhood and adolescence still carries a 
particularly poor prognosis’ stood out to me, along with the very chaotic and 
tormented picture I had picked to go along with it. I took the poster down before my 
patient came.  
Along the way of the PhD, I have often thought back to this incident and again posed 
the questions to myself along with reflections on what to tell patients. A few times I 
even thought to myself that I would rather have picked a different area of research, 
just to have more good stories to share.  
Now, with all the results ready, I think I am ready to answer the questions truthfully 
and honestly, while at the same time considering what things I would like my treating 
clinician to pinpoint if the situation were reversed.  
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Everybody needs to retain some hope. In situations where we are down on our luck, 
feeling despair and powerlessness, we need a chance to believe that it will get better. 
It does not mean we should all be ‘happy-go-lucky’ preachers and only share 
optimism and recovery tales. For some patients, that would be overlooking their 
despair and turmoil.   
But even though the research points to more severe outcomes for schizophrenia than 
most other mental disorders, it also points to remission for some, benign outcomes for 
others and improvement for the majority. Even in EOS, the prognosis do not seem as 
poor as previously believed. Twenty percent in our register-based EOS sample were 
never admitted to hospital during follow-up.   
So, when speaking to my patients, I will share my knowledge of the field. But it will 
not be all gloom-and-doom talk. As for child and adolescent schizophrenia, I will let 
them know that it is has been associated with a more severe outcome than what is 
known from AOS – but that some studies, including my own of all cases diagnosed 
in Denmark over almost two decades, does not confirm this difference for the long-
term outcomes on most measures. Perhaps some of the negative findings from prior 
studies were due to very high number of drop-outs or selection bias from only 
investigating patients in specialized settings. Then, I will move away from all the 
percentages, the ORs, confounders, ‘significant findings’ and p-values. And I will 
bring back the talk to the individual patient – talk about his/her personal strengths and 
assets, how his/her surroundings, life events and support system may benefit him/her 
towards a better outcome, towards a personal recovery. How he/she can reduce the 
risk factors and stressors. And I will remember that as a clinical and also as a 
researcher sometimes my job is just to listen and help facilitate while people find their 
own way. And at times, they will need me or someone else to carry the flashlight.  
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CHAPTER 7: CONCLUSION 
Having investigated EOS from several different angles; reviews of other studies; 
validation of schizophrenia diagnoses in Denmark; and register studies of outcome, I 
will now summarize the findings related to the initial research questions:  
 
a) What do we currently know about the outcome of EOS and does it differ 
from adult onset?  
- Although prior studies have pointed to a more severe course of 
EOS, this Danish nationwide register-based study of a large EOS 
sample could not confirm a difference on the majority of outcomes. 
In line with Immonen’s meta-analysis48 and studies from EPPIC47 
and ÆSOP200, our results point to age of onset being less predictive 
for outcome than previously thought.  
 
b) What is the validity of schizophrenia diagnoses from child and adolescent 
psychiatric departments in Denmark and are the diagnoses correctly 
registered in the DPCRR?  
- Ten percent of schizophrenia diagnoses in children and adolescents 
are misclassifications; however, the vast majority of the 
misclassifications are still in the schizophrenia spectrum. Of the 
cases diagnosed with schizophrenia in the clinic, experienced raters 
evaluated 83.5% to be correct and 91.8% as being in the 
schizophrenia spectrum. Although EOS can be diagnostically 
challenging, we were in line with other studies in concluding that it 
can be reliably diagnosed by experienced clinicians conducting 
thorough assessments. 
 
c) Based on Danish register-based data, are there differences between EOS and 
AOS in the following:  
 
- Number of inpatient days in short- and long-term outcome? 
 
With regard to short-term outcome, defined as the first 2 years of 
diagnosis, patients with EOS spend more days in hospital than those 
with AOS, but for long-term outcome the number of annual inpatient 
days did not differ. Our sensitivity analyses point to the initial difference 
as a potential effect of different treatment patterns in child and 
adolescent psychiatry versus adult psychiatry. Childhood adversities and 
co-morbid substance use disorder were more associated with inpatient 
days than early- vs. adult-onset. 
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- Premorbid characteristics 
In study 3, patients with EOS and AOS were strikingly similar with 
regard to premorbid characteristics as measured in the register (disorders 
prior to schizophrenia and a number of parental variables: 
predisposition, divorce, death, substance use disorder, incarceration, 
psychiatric admission and longer somatic admission). Only premorbid 
substance use disorder in patients reached a significant and clinically 
relevant difference, possibly owing to the age difference. It is important 
to bear in mind that we were not able to measure the degree of premorbid 
developmental difficulties in the patients or their cognitive function as 
these measures are not available in the registers. In the validation study, 
43% of the patients with EOS had experienced problems with speech 
and language development, social development or psychomotor 
development during childhood.    
- Psychiatric outcome and measures of psycho-social functioning 
For psychiatric outcomes, EOS and AOS were similar with regard to 
long-term admissions, inpatient days and heavy use of inpatient days. 
Three differences emerged: fewer patients with EOS patients were never 
admitted and more patients with EOS had experienced an involuntary 
admission; both differences were minor (≤ 5%). Finally, more patients 
with AOS had a diagnosis of substance use disorder, which may be 
attributed to their older age.  
For psychosocial outcomes, patients with EOS were less likely to have 
completed education above law-mandated school, even 5 years into 
adulthood. Though this difference was large between the two groups, 
many patients with AOS would have reached this level of education 
before the development of schizophrenia. More patients with EOS were 
in unsupported work or education at end of follow-up.  
The thesis do not touch upon all aspect of outcomes of EOS and other important issues 
remain, e.g. suicide rates and all-cause mortality as well as more detailed studies of 
education and vocational outcomes would be highly relevant to investigate further in 
the large cohort of EOS patients identified by the DPCRR.  
Still, looking ahead, more emphasis should be placed on risk factors for poor outcome, 
some of which can be prevented or at least reduced, and the knowledge of such risk 
markers can help us identify them in the individual patient in order to intervene more 
efficiently.  
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ENGLISH SUMMARY 
Early-onset schizophrenia (EOS), usually defined as onset of symptoms prior to the 
age of 18 years, has been associated with poor outcomes for several decades. Less 
than 10% of all patients with schizophrenia are diagnosed in childhood and 
adolescence. The low prevalence makes it difficult to conduct large-scale studies 
investigating EOS, and studies  are often biased by high drop-out rates as well as 
selection bias. In the past few years, a number of studies has been published pointing 
to EOS being more similar to AOS than previously thought in terms of outcome, with 
some even suggesting a better prognosis for early-onset psychotic disorders.  
This thesis investigates the outcome of EOS through a systematic review and with 
data from the Danish, nationwide registers. Furthermore, a validation study of the 
schizophrenia diagnoses registered in children and adolescents in the Danish 
Psychiatric Central Research Register (DPCRR) was conducted to assess the 
concordance between the diagnosis described in the psychiatric records and the 
register-based diagnosis as well as to evaluate the quality of the clinical diagnosis of 
schizophrenia by rating psychiatric records.  
The systematic review of long-term outcome of EOS included studies in English-
language journals published after 1980 with at least one year of follow-up. Twenty-
one studies were included with a total of 716 patients. Studies were included if a 
majority had EOS, but approximately half of the studies also included other psychotic 
disorders. Patients were followed for a mean of 13 years with a range of 1.5-42 years. 
Mean age of onset was 14.9. In the studies of patients with EOS only, 15.4% had a 
good outcome, 24.5% a moderate outcome, and 60.1% a poor outcome. In the full 
sample, also including some patients with other psychotic disorders, 17.2% had good 
outcome, 28.2% moderate, and 54.6% poor outcome.  
In the validation study, 178 psychiatric records of a random sample of 200 children 
and adolescents diagnosed with schizophrenia in the period 1994–2009 were 
retrieved. Eleven percent of the DPCRR registered schizophrenia diagnoses were 
registration errors, and the diagnostic validity of DPCRR registered schizophrenia was 
75.3% for schizophrenia, with 83.5% of the records in the schizophrenia spectrum. Of 
the clinically diagnosed schizophrenia, the raters confirmed 83.5% to be correct, with 
91.8% meeting criteria for schizophrenia spectrum disorders. Schizophrenia 
diagnosed during an inpatient contact had higher validity and fewer registration errors. 
In conclusion, EOS diagnoses in DPCRR are valid for register research, but diagnostic 
accuracy can be improved by including only patients diagnosed during 
hospitalization.  
The third study included 16,337 patients registered with a schizophrenia diagnosis in 
the DPCRR between 1996 and 2012 before the age of 40 years, 1,223 of the sample 
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had early-onset. Mean age of onset in the patients with EOS was 16.1 ± 1.7 years and 
27.7 ± 6.3 years among patients with AOS. Duration of follow-up was 8.5 ± 4.5 years 
for patients with EOS and 9.6 ± 5.0 years in the AOS group). The majority of the 
sample were adults at the end of follow-up, with only 77 patients in the EOS group 
below the age of 18 (6.3% of EOS). The primary outcome measure was inpatient days 
during short- and long-term outcome. In the short-term outcome, the patients with 
EOS had more inpatient days, but after the initial two years, there was no difference 
between the two groups. Substance use disorders and being placed in out-of-home 
care during childhood were stronger associated with inpatient days in long-term 
follow-up than age of onset. For the secondary outcomes, there were many similarities 
between patients with EOS and AOS, but EOS had a longer length of first admission, 
were less likely to never be admitted and more likely to have experienced involuntary 
admission and fewer had achieved an educational level above law-mandated school, 
even when restricting analyses to patients at least 23 years of age. Patients with AOS 
were more likely to have comorbid substance use disorders and at the end of follow-
up, more patients with AOS were dependent on social benefits as primary source of 
income. 
To conclude, the outcome of EOS may be more similar to outcome of AOS than 
previous studies have suggested, and the register-data could not confirm a particular 
poor prognosis for patients with EOS. The thesis have not assessed all outcomes of 
EOS and several topics would be worth exploring further by use of the large sample 
of patients with EOS identified by the DPCRR, in particular mortality and suicide-
risk as well more detailed studies of educational and vocational outcomes. Other 
factors not related to age may be more important for prognosis, such as substance use 
and childhood adversities, which must be considered when addressing preventive 
strategies as well as intervention strategies.  
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DANSK RESUME 
Tidlig skizofreni defineres som debut før det 18. år og er forbundet med en dårlig 
prognose. Færre end 10% med skizofreni, diagnosticeres med tidlig skizofreni. Den 
lave prævalens gør det vanskeligt at undersøge forløbet af tidlig skizofreni, og der er 
ofte stort frafald ved longitudinelle studier. De seneste år er der publiceret studier, der 
peger på, at prognosen ved tidlig skizofreni er mere lig skizofreni med debut i 
voksenalderen, og nogle finder bedre forløb ved tidlig skizofreni.  
Afhandlingen undersøger forløbet af tidlig skizofreni gennem et systematisk litteratur-
studie samt via data fra de landsdækkende, danske registre. Derudover består 
afhandlingen af et validerings-studie af skizofreni-diagnosen registreret hos børn og 
unge i det Danske Psykiatriske Centrale Forsknings Register (DPCRR). 
Valideringsstudiet fokuserer på overensstemmelsen mellem register-diagnosen og 
diagnosen, der er noteret i journalen og på, om diagnosen er stillet efter de 
diagnostiske kriterier i henhold til ICD-10 og således vurderes fagligt valid.  
Det systematiske litteratur-studie inkluderede studier fra engelsksprogede artikler 
udgivet efter 1980 med mindst et års follow-up, hvor hovedparten af patienterne havde 
tidlig skizofreni. 21 studier med i alt 716 patienter blev inkluderet, knap halvdelen af 
studierne inkluderede også patienter med tidlig debut af andre psykotiske lidelser, 
primært inden for skizofreni-spektret. Den gennemlige opfølgningstid var 13 år, og 
den gennemsnitlige alder for debut af psykotiske symptomer var 14,9 år. Forløbet af 
skizofreni var kategoriseret i ”mildt”, ”moderat” og ”svært”. I studier af patienter med 
tidlig skizofreni havde 15,4% et mildt forløb, 24,5% et moderat forløb og ca. 60,1% 
et svært forløb. Blandt hele gruppen, inklusiv patienter med andre psykotiske lidelser, 
havde 17,2% et mildt forløb, 28,2% et moderat forløb og 54,6% et svært forløb.  
I valideringsstudiet lykkedes det at lokalisere 178 psykiatriske journaler ud af et 
tilfældigt udtræk på 200 børn og unge, der var registreret i DPCRR med en skizofreni-
diagnose i perioden 1994 – 2009. Elleve procent af diagnoserne var registreringsfejl, 
hvor patienten ifølge journalen ikke var blevet diagnosticeret med skizofreni. Blandt 
register-diagnoserne blev 75,3% bekræftet af raterne som skizofreni og 83,5% som 
indenfor skizofreni-spektret. Blandt de kliniske skizofreni-diagnoser bekræftede 
raterne 83,5% af diagnoserne som skizofreni og 91,8% som inden for det skizofrene-
spektrum. Diagnoser foretaget under indlæggelse havde en højere validitet pga. færre 
registreringsfejl. Det konkluderes, at skizofreni-diagnoser fra DPCRR kan bruges til 
register-forskning, og at diagnostisk præcision kan øges ved at fokusere på patienter 
diagnosticeret under indlæggelse eller med flere forløb.  
Registerstudiet af forløbet ved skizofreni inkluderede 16,337 patienter med skizofreni 
registeret i DPCRR mellem 1996 og 2012, der var diagnosticeret før de fyldte 40 år, 
af disse var 1223 diagnosticeret før det 18. år og udgjorde gruppen med tidlig 
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skizofreni. Gennemsnitsalder for diagnose ved tidlig skizofreni var 16.1 ± 1.7 år og 
ved voksen-debut 27.7 ± 6.3 år. Patienterne blev gennemsnitligt fulgt i registrene i 9,5 
år (tidlig skizofreni 8.5 ± 4.5 år, voksen-debut 9.6 ± 5.0 år). Indlæggelsesdage var det 
primære outcome-mål. Patienter med tidlig skizofreni havde flere indlæggelsesdage i 
de første to år efter diagnosen, men herefter var der ingen forskel på de to grupper, 
mens komorbide misbrugsdiagnoser samt anbringelser i løbet af barndommen var 
stærkere associeret til indlæggelsesdage. Forskellen i starten af forløbet kan muligvis 
forklares med anderledes indlæggelsesmønstre i børne- og ungdomspsykiatrien i 
forhold til voksenpsykiatrien. På de øvrige mål for forløb lignede de to grupper 
hinanden på mange områder, men patienter med tidlig debut havde længere varighed 
af første indlæggelse, færre blev aldrig indlagt og flere oplevede at blive 
tvangsindlagt.  Endvidere opnåede færre med tidlig debut at færdiggøre en uddannelse 
udover folkeskolen, selv ved det fyldte 23. år. Patienter med debut i voksen-alderen 
havde hyppigere en komorbid misbrugsdiagnose og var oftere på offentlig forsørgelse 
som den primære indtægtskilde ved afslutning af follow-up. Antallet af patienter med 
EOS i registerstudiet er, så vidt vides, den største gruppe med EOS undersøgt til dato.  
På baggrund af afhandlingens resultater konkluderes, at forløbet af tidlig skizofreni 
ligner forløbet af skizofreni med debut i voksen-alderen mere end tidligere antaget, 
og vi har ikke kunnet påvise gennem register-data, at skizofreni hos børn og unge har 
en værre prognose. Afhandlingen har ikke afdækket alle områder af tidlig skizofreni, 
og der er områder, det vil være meget relevant at belyse gennem det store sample 
identificeret gennem DPCRR – det kunne f.eks. være mortalitet og selvmordsadfærd, 
ligesom uddannelse- og arbejdstilknytning kan undersøges i et mere detaljeret design.   
Der bør også være fokus på, at der er andre faktorer, der ikke har at gøre med 
debutalder, der kan være væsentlige for prognose og forløb, så som stof- og 
alkoholmisbrug samt belastninger og traumer i barndommen. Disse faktorer må 
adresseres både i forebyggelsesøjemed samt i forhold til interventionsindsats.  
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APPENDIX A: CO-RATER CHECKLIST FOR VALIDATION STUDY 
Rater assignment 
1. The rater is provided with a printed check-list (see next page) and material 
from the psychiatric record (e.g. discharge summary, diagnostic interview, 
observations, anamnestic information, psychological assessment)  
2. The rater must tick the relevant spaces ___ and write comments where it is 
requested, marked with __________.  
3. After filling out the form, the rater must use the information to evaluate the 
likeliness of correct schizophrenia diagnosis on the following scale:  
 
___ 1) Correct  ___ 2) Maybe ___ 3) Not correct 
 
If the rater ticks ‘maybe’, the reason should be specified (e.g. insufficient information, 
vague description of symptoms, unclear duration of symptoms required to classify 
schizophrenia or presence of other diagnoses potentially explaining the 
symptomatology). If insufficient information, contact DLV to see if additional record 
material is available.  
If the rater ticks ‘maybe’, an arrow should indicate if the rating is leaning towards 
correct or incorrect.  
How to fill out the checklist 
1. Name & ID: Provide patients initials and study-assigned ID.  
2. Start & end date of this contact: Is already coded (Specify first date of this 
contact (admittance date or date of first contact in out-patient facility) and the 
date the patient was discharged from hospital or out-patient facility) 
3. Cognitive decline: Tick ‘yes’ if it is described that the patient does not have the 
same cognitive or educational capacities as previously. The knowledge may stem 
from psychological testing or could be based on school information.  Tick ‘no’ if 
it is described that there is no such decline and tick ‘not mentioned’ if the record 
does not give information regarding possible decline.  
4. Family disposition for schizophrenia: Tick ‘yes, 1st degree relatives’ if 
father/mother/full sibling or offspring has schizophrenia, tick ‘yes, 2nd degree 
relatives’ if a relative with whom the patient shares 25% of genes has 
schizophrenia (grandparent, grandchild, uncle, aunt, nephew, niece, half-sibling), 
tick ‘no disposition’ if it is explicitly stated that there is no known disposition, 
tick ‘not mentioned’ if the material does not mention dispositions. Tick ‘other 
disposition’ and write which if patient is disposed to other psychiatric illness than 
schizophrenia.  
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5. Drug use: Specify if drug use has been present or is present and specify drug of 
choice.  
6. Onset type: Insidious vs. acute: Tick ‘insidious’ if presence of 
neurodevelopmental difficulties and attenuated/sub-syndromal symptoms for > 1 
month preceding full psychosis. Tick ‘acute’ if preceding symptoms and 
difficulties have been absent or present for less than 1 month prior to full 
psychosis. 
7. Duration of untreated psychosis: Specify length of duration of untreated 
psychosis. The first date that the patient is offered antipsychotic medication is 
defined as the last day of untreated psychosis. Thus, if the patient has had 
psychotic symptoms for 1 year before being offered medication, the duration is 1 
year. Tick ‘not mentioned’ if the record does not give information on this.  
8. Anti-psychotic medication prescribed: Tick yes and write prescription (type 
and dose).  Tick ‘no’ if the patient is not on medication at discharge and tick ‘not 
mentioned’ if the record gives no information on this.  
9. Diagnostic interview used for diagnosis: Tick ‘yes’ if an interview format is 
mentioned and if possible, specify which one. If the record does not specify the 
type of interview but mentions the use of a diagnostic interview, tick yes and 
write ‘not mentioned’ under ‘which’. If the record states that a diagnostic 
interview has not been used, tick ‘no’..  
The smaller checklist in the square consists of the diagnostic requirements for a 
schizophrenia diagnosis in the ICD-10: 
10. 1st rank symptoms: Tick ‘yes’, ‘no’ or ‘not mentioned’ according to which 
information is given in record. If ‘yes’, tick which 1st rank symptom or ‘not 
mentioned’ if this is not specified 
11. Other symptoms of schizophrenia: Tick ‘yes’, ‘no’ or ‘not mentioned’ 
according to which information is given in the material. If ‘yes’ tick also which 
symptom or ‘not mentioned’.  
12. Duration of illness: Specify <1 month, >1 month or ‘not mentioned’. If <1 
month, specify if this could be due to medication.   
13. Finally, the rater should evaluate the likelihood of schizophrenia based on 
the information available. Even if it is not possible to have all the information 
needed for diagnosis, the rater must state whether he/she feels confident that the 
examination has been thorough and the diagnosis given is thought to be a best 
estimate. The rating ‘maybe’ is available for cases when the rater is in doubt. 
Remember it is possible to request additional information as DLV has selected 
parts of the full record for the rater to use.  
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ID_nr:  [ _ ] [ _ ] [ _ ] -- [ _ ] [ _ ] [ _ ]  Initials  [ _ ] [ _ ] [ _ ]  
Period for rating (month/yr – month/yr): ________  – _________ 
Cognitive / educational decline:   
___ Yes  
___ No   
___ Not described 
 
Familiære dispositioner 
___ Yes, 1st degree schizophrenia  
___ Yes, 2nd degree schizophrenia   
___ Yes, other: ____________________ 
___ No familiar predisposition  
___ Not described 
 
Substance use 
 ___ Yes, throughout the course of the disorder 
Elaborate __________________________   
 ___ Yes, previously: _________________ 
 ___ No drug-use now or previosly 
 ___ Not described 
 
 
 
 
 
 
 
 
 
 
 
Type of onset 
___ Insidious 
___ Acute (<1 mo) 
___ Not described  
 
DUP 
___ Specify duration ________________ 
___ Not described  
 
Anti-psychotic medication prescribed 
___ Yes, elaborate type 
__________________________________   
___ No   
___ Not described 
 
Semistructured interview used 
___ Yes: ___________________________ 
___ No 
___ Not described 
 
 
 
iv 
 
ID_nr:  [ _ ] [ _ ] [ _ ] -- [ _ ] [ _ ] [ _ ]  Initials  [ _ ] [ _ ] [ _ ]  
Rater’s evaluation of the patients’ diagnosis of schizophrenia based on record material: 
 
___ 1) Correct   ___ 2) Maybe  ____ 3) Incorrect 
(reasons for maybe: insufficient information, vague description of symptoms, unclear duration 
of symptoms required to classify schizophrenia or presence of other diagnoses potentially 
explaining the symptomatology).  
When rating maybe, specify if the rating is leaning towards ‘correct’ or ‘incorrect’. 
Raters’ best-estimate diagnosis: _____________________________ 
Use back page for comments.  
 
ICD-10 criteria for schizophrenia (F20.x) 
1st rank 
symptoms 
(not necessary 
for diagnosis, 
but sufficient for 
diagnosis if at 
least one clear 
FRS)) 
___ Yes         Tick the relevant below  
 
___ Thought echo, -insertion, -withdrawal or -
broadcasting               
___ Delusion of control or delusional perception                 
___ Voices giving running commentary, discussing 
patient among themselves or stemming from 
patient’s body 
___ Bizarre delusions  
___Not mentioned which 1st rank symptom  
(see detailed description in the appendix) 
___ No  
 
 
___ Not 
mentioned 
Other 
symptoms of 
schizophrenia 
(at least 2 if no 
FRS) 
___ Yes         Tick the relevant below 
 
___  Persistent hallucinations without affective 
content, often accompanied by half-formed 
delusions 
___  Thought/language disturbance (incoherent or 
irrelevant speech, neologisms, blocking, etc.) 
___  Catatonic behavior  
___  Negative symptoms  (anhedonia, asociality, 
affective flattening, alogia, amotivation – not due to 
depression) 
___  Not mentioned which symptoms  
(see detailed description in the appendix) 
___ No  
 
 
___ Not 
mentioned 
Duration of 
illness  
 
___ < 1 month                  Due to medication __  
___ > 1 month 
 
Specify duration: ______________weeks, months, 
years (circle which) 
 
___ No  
 
 
___ Not 
mentioned 
 
v 
 
Definitions from the ‘The ICD-10 Classification of Mental & Behavioral 
Disorders, Clinical descriptions and diagnostic guidelines’. 
1st rank symptoms: 
A. Thought echo, thought insertion or withdrawal, and thought broadcasting;  
B. Delusions of control, influence, or passivity, clearly referred to body or limb movements 
or specific thoughts, actions, or sensations; delusional perception; 
C. Hallucinatory voices giving a running commentary on the patient's behavior, or 
discussing the patient among themselves, or other types of hallucinatory voices coming 
from some part of the body; 
D. Persistent delusions of other kinds that are culturally inappropriate and completely 
impossible, such as religious or political identity, or superhuman powers and abilities 
(e.g. being able to control the weather, or being in communication with aliens from 
another world); 
 
Other symptoms (at least 2 needed for diagnosis):  
E. Persistent hallucinations in any modality, when accompanied either by fleeting or half-
formed delusions without clear affective content, or by persistent over-valued ideas, or 
when occurring every day for weeks or months on end;  
F. Breaks or interpolations in the train of thought, resulting in incoherence or irrelevant 
speech, or neologisms; 
G. Catatonic behavior, such as excitement, posturing, or waxy flexibility, negativism, 
mutism, and stupor; 
H. Negative symptoms such as marked apathy, paucity of speech, and blunting or 
incongruity of emotional responses, usually resulting in social withdrawal and lowering 
of social performance; it must be clear that these are not due to depression or to 
neuroleptic medication; 
I. A significant and consistent change in the overall quality of some aspects of personal 
behavior, manifest as loss of interest, aimlessness, idleness, a self-absorbed attitude, and 
social withdrawal. In Danish psychiatry, this item is listed as ‘negative symptoms’ 
also.  
 
 
 
 
 
ID _____   Birth Mo/Year ______
Sex Hospital, Region
Siblings, number x/N
Household (parents, divorced, mom/dad, other)
Mom current work
Dad current work
Birth complications y/n if y, desc: 
Birth preterm y/n Gestation wks 
Birth weight Birth lenght
Language devl. normal y/n if n, desc
Social devl normal y/n if n, desc
Motor devl normal y/n if n, desc
Ageapp relations y/n if n, desc
Dispositions y/n
SZ if y, who
Bipolar if y, who
Depression if y, who
Anxiety if y, who
Other if y, who
Intelligence test y/n if y, year/type
Total IQ details
Trauma y/n if y, cont. 
Sexual if y, type
Violent if y, type
Other if y, type
Belastninger y/n if y, cont
School change if y, N
Parental separation if y, type
Parental death if y, type
Parental substance abuse if y, type
Victim of bullying if y, type
Other if y, type
Previous interventions if y, continue
PPR (school/kindergarten interventions) if y, type
Social services if y, type
Private psychologist if y, type
Other if y, type
ID _____   Birth Mo/Year ______
Previous suicidal ideation Suicidal idea during psyc.
Previous attempts, y/n Attempts dur psyc.co
Previous agg. Impulses y/n Agg. dur psyc.co
Previous crime y/n Crime dur psyc.co
Previous selfharm y/n Selfharm dur psyc.co
Loss of function, school y/n if y, desc.
Loss of function, social y/n if y, desc.
Loss of function, cognitive y/n if y, desc.
Psychiatry prior to SZ:
1st dx
2nd dx
3rd dx
4th dx
Admissions prior or during X admission at time of SZ
1st adm x year and lenght
2nd adm year and lenght
3rd adm year and lenght
Medication prior or during
1st AP
2nd AP
3rd AP
4rd AP
Polypharma y/n
Max nr of AP
Weight gain during AP, kg period:
Antidepressive medication
Anxio
Other
Noncompliance y/n
MEDICATION AT DISCHARGE: 
Notes on medication
X medication 
at time of SZ
ID _____   Birth Mo/Year ______
Age first psychiatric contact Age SZ contact
Age at SZ onset
Referal dx at SZ contact
Dx at IP / OP if IP, frivil y/n
Onset type (insi, acute, sub-acu) DUP, wks
ICD-10 criteria
DX Diagnostisk interview y/n if y, type
DX_first rank y/n if y, cont.
DX Control delu y/n DX Bizz delus y/n
DX Body delusions y/n DX Delusional perception y/n
       DX FRS thought disorders y/n
DX Non-aff. Hall. y/n if y, cont. 
DX Auditory y/n Føle hall, y/n
DX visual y/n Taste / olfactory y/n
DX Thought distu y/n
DX catatonia y/n
DX negative symp y/n if y, type
DX duration, wks
DX somatic screen, y/n
DX Drug-use currently y/n if y, type
Drug-use previously y/n if y, type
Discharge diagnoses: 
Miss-classifications in DPCR, y/n
SZ diagnosis valid Y/N/MAYBE
Dx by rater
Notes on symptoms
Notes on file
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Table 1 Overview of the 21 Studies
Sex Outcome (%)
Authors Diagnosis Period of
Diagnosis
N Dropout
N (%)
Age at
onset (yrs.)
Female Male Duration of
follow-up (yrs.)
Outcome criteria Original outcome
ratings
Good Moderate Poor
N (%) N (%)
Hassan et.al
(2011)
SZ, psychosis
NOS
2003-2010 37 14 (27) Mean = 12.2 23 (62) 14 (38) Mean =3.2 CGAS: Good: ≥ 70 27.0 48.7 24.3
Moderate 40-70
Poor: ≤ 40 and
partial or no
remission.
Ledda et al.
(2009)
SZ 1992-2002 15 2 (12) Mean = 15.1 9 (53)* 8 (47)* 5 GAF* 11.8 60.0 27.6
Reichert
et al. (2008)
SZ & SZ-AFF 1990-2000 27 59 (80) Mean = 15.5 8 (30) 19 (70) Mean= 13.4 Employment 3,7% university study 22.2 51.8 25.9
18,6% regular work
48,1 sheltered work
25,9% unable to work
3,7% unemployed
Remschmidt
et al. (2007)
SZ 1920-1961 38 0 (0) 5-14 23 (61) 15 (39) Mean= 42 GAS: 5.8 23.7 60.5
Good >71
Moderate: 41-70
Poor: <40
Fleischhaker
et al. (2005)
SZ 1983-1988 81 20 (20) 11-18 36 (44) 45 (56) 4-11 GAF: 19.80 38.20 42.00
Poor: <40
Moderate: 41-70
Good >71
Helgeland
et al. (2005)
SZ 1963-1978 9 N.A 13-17 1 (11) 8 (89) Mean= 28,1 Social disability
(medication,
means of income,
living situation)
All on antipsychotic
medication at
follow-up, all on
disablement benefits,
none living in an
ordinary home
0,00 0.0 100.00
Röpcke et al.
(2005)
SZ, SZ-AFF,
schizo-phreni-
form disorder
1979-1988 39 16 (29) Mean = 16 19 (49) 20 (51) 10.2-21.2 GAS: 21.00 28.00 51.00
Good >60
Moderate: 51-60
Poor: <51
Jarbin (2003a) SZ 1982-1993 30 58 (66) 11.8 - 18.7 11 (37) 19 (63) 5.1-18.2 GAF (or employment
if GAF not available)
79% very poor 3.00 0.00 97.00
18% poor
3% good
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Table 1 Overview of the 21 Studies (Continued)
Hollis, (2000b) SZ 1973-1991 51 17 (25) Mean = 14.0 22 (43) 29 (57) 4-22 Remission at
follow-up
12.00 40.00 48.00
Lay et al. (2000) SZ & SZ-AFF
(ICD-9)
1976-1987 65 31 (32) 11,5-17,9 38 (59) 27 (41) 10 Social disability
(DAS-scale and global
evaluation on a
6-points scale)
12,5% no
dysfunction,
20.00 44.00 36.00
7,8% minimum,
14,1% obvious,
29,7% serious,
31,3% very serious,
4,7% maximum
dysfunction
McClellan
et al. (1999)
SZ 11 7 (39) 11-16 3 (27) 8 (73) 2 Course of illness
and description
of impairment
0.0 9.00 91.00
Aarkrog (1999) SZ, SZ-AFF 1968-1976 28 N.A. 12-20
(M= 16.8)
7 (25) 21 (75) 17-26 GAS 3.6 17.9 78.5
Eggers et al.
(1997)
SZ (DSM-III-R) 1925-1961 44 27 (38) 6-14 25 (57) 19 (43) Mean= 42 Social disability
(Eggers social
scale)
1-2: Good remission
GAS >70
25.00 25.00 50.00
3-4: Moderate
remission <GAS 51
5-6: Poor
remission - < GAS 40
Maziade et al.
(1996)
SZ (DSM-III-R) 1968-1990 40 37 (48) 10-17 13 (33) 28 (67) 14.8 GAS 5.00 15.00 80.00
Werry et al.
(1994)
SZ, Schizo-
phreni-form
disorder
1968-1990 53 41 (36) 7-17 22 (42) 31 (58) 4.3 Living situation 20.7 17.00 62.30
Rund 1994 SZ (ICD-9) 1980-1990 24 0 (0) 13,1-17,9
(Mean= 16)
8 (33) 16 (67) 2 GAS 0 21.0 79.0
Cawthron
et al., 1994
SZ (ICD-9) 1975-1986 9 10 (53) 14-18 - - 2-13 Adult Personality
Functioning
Assessment
Seven (78%)
continuously ill.
None of these
employed or
married; extremely
poor social
functioning. The
two recovered
patients (22%)
were ill for only
2% of the follow-
up period.
22.00 0.00 78.00
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Table 1 Overview of the 21 Studies (Continued)
Asarnow et al.
(1994)
SZ 1980-? 18 3 (14) 6-11,3 5 (24) 13 (76) 2-7 CGAS 28% good
outcome
CGAS >60, 28%
28.00 28.00 44.00
>60 = good
51-60 =moderate moderate
improvement
CGAS 51–60, 28%
<51= poor
minimal
improvement
CGAS <51, 17%
deteriorating
CGAS <41
Gillberg et al.
(1993)
SZ (DSM-III /
ICD 9)
Born
1960–1982.
23 0 (0) 13-19 9 (39) 14 (61) 11-17 Overall register
data outcome
13% overall
possibly good
13.00 9.00 78.00
9% intermediate
outcome
78% extremely
poor
Krausz et al.
(1993)
SZ, mood
disorders,
psychoses (PSE)
1972-1978 55 6 (10) 14-18 28 (51) 27 (49) 11-16 Mental and social
handicaps rated
according to
Brown (1966),
20% inpatient, 26% 29.6 18.5 51.9
seriously
handicapped
16% handicapped
but employed
26% not
handicapped
12% no findings
Inoue et al.
(1986)
EOS and acute
psychotic
episode (DSM-III)
1971-1981 19 N.A. 10-17 9 (47) 10 (53) 3 Ability to work 47% unable
to work
16.00 37.00 47.00
16% limited
work ability
21% working
at a lower level
than previously,
16% working
as before
If not otherwise specified: GAF: Global Assessment of Functioning >70 =Good; 70-51 =Moderate; <51 = poor. SZ: Schizophrenia. SZ-AFF: Schizoaffective disorder. CGAS: Children Global Assesment of Functioning Scale.
GAS: Global Assessment Scale. N.A. = Not assessed. PSE = Present State Examination. *Based on N at baseline.
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used for classifying the study [5,38,49,51].
one study, there was no information on sex distri-
on [49], and only a minority of studies reported out-
es stratified for sex [1,11,41,52]. Multiple studies
d sex differences without reporting stratified data.
e period of diagnosis considered studies including
the formula of rho
small effect, 0.3 a m
Data analyses were
(SPSS, Chicago).
Results
le 2 Outcome by diagnoses based on 21 studies (N=716)
Percentages of subjects by diagnosis
ome variable EOS Mixed
Mean SD Range Median Mean Rank Mean SD Range Media
N=422 N=294
15.4 7.7 0-28 15.8 300.05 19.6 9.1 0-29 21.0
erate 24.5 14.6 0-60 23.7 299.75 33.6 12.9 18-52 37.0
60.1 18.9 27-100 60.5 410.59 46.8 17.8 24-79 47.0
mensen et al. BMC Psychiatry 2012, 12:150
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nally, diagnoses were considered by dividing the
-set into studies containing only patients with EOS
studies including both patients with schizophrenia
patients with other psychotic disorders, i.e., psych-
(MIX).
istical analyses
three categories of “good”, “moderate”, and “poor”
e calculated in percentages and rounded to the near-
decimal. In order to take into account the large vari-
n in sample sizes, weighted percentages were
ulated by weighting each reported rate with the size
he study group. All analyses were based on adjusted
ple sizes at follow-up assessments rather than actual
ple sizes after patient recruitment.
ue to consistent and significant deviation of the data
the normal distribution, non-parametric tests were
in the analyses. The effects of the four predicting
ables mentioned above on the three outcome mea-
s were analyzed using the Mann Whitney test with
ferroni adjustments of p-values correcting for mul-
testing. Considering five tests, findings were signifi-
The current review
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characteristics and
Table 1. The sampl
with a mean group
considerable differe
duration of follow-
data. Diagnostic cla
the period in whic
the fact that patien
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ICD-10 criteria. In
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studies reported on
The mean durati
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based on 707 patien
included. Repeated
six samples and fin
[8,11,29,35,41,53,54
these studies are n
analysis because bo
up periods (except
differed considerablt at the p = 0.01 level and highly significant at
0.002. In addition, effect sizes were calculated using
was divided into a gro
group of MIX studies (
le 3 Outcome by attrition rate based on 18 studies (N= 660)
Percentages of subjects by dropout ra
ome variable Low dropout (<28%) High dropout (>28%)
Mean SD Median Mean Rank Mean SD Median Mean Ra
N=342 N=318
18.8 8.2 19.8 324.72 17.0 8.0 20.7 340.77
erate 32.0 12.8 38.2 370.67 25.2 15.6 25.0 291.96
49.1 15.3 48.0 293.44 57.7 21.3 51.0 373.99Page 7 of 16z/√N), where 0.1 is indicating a
erate effect, and 0.5 a large effect.
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, type of evaluation, and missing
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he studies were conducted given
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reasing reliance on DSM-IV and
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a total of 394 males (56.5%) were
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Table 4 Outcome by measures of functioning based on 21 studies (N=716)
Outcome variable Percentages of subjects by measures of functioning
GFS SSF Analysis
ean
EOS
Good 0.0
Mod 2.0
Poor 9.80 16540 −4.56 <.001 0.22
MIX
Good 7.0
Mod 9.6
Poor 3.4
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Good
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le 1 contains columns reporting the outcome criteria
in the various studies, the original outcome ratings,
the outcome (in%) divided into the three categories
good,” “moderate,” and “poor,” as calculated and
d by the us, which we based on the data in the pre-
ng column containing the original outcome ratings.
come in samples of pure EOS vs. mixed psychotic
rders
shown in Table 2, studies only containing EOS
ents came up with a rate of 15.4% with a “good” out-
e, whereas 24.5% experienced a “moderate” out-
e, and 60.1% experienced a “poor” outcome. In the
samples, the figures were 19.6% with “good” out-
e, whereas 33.6% experienced a “moderate” out-
e, and 46.8% experienced a “poor” outcome. In each
ome category, though, the variation across studies
ed to be remarkably high.
samples. Consequen
poor outcome was
the EOS samples. A
Effects of drop-out r
Dropout rates in 17
of 0% and a maxim
dichotomized at the
as having a high (>
The effect of the a
meters was assessed
highly significant
“poor” outcome gro
groups (see Table 3
was significantly h
compared to the hi
posite was the case
higher rate of poor
Mean SD Median Mean Rank Mean SD Median M
N=222 N=200
14.3 7.8 15.8 185.75 16.6 7.5 20.7 24
erate 27.0 12.8 28.0 220.02 21.7 12.8 17.0 20
58.7 15.3 44.0 186.00 61.7 15.3 62.3 23
N=128 N=166
15.0 11.1 21.0 122.18 23.1 0.4 20.0 16
erate 30.5 12.1 28.0 131.75 36.0 1.0 44.0 15
54.5 22.6 51.0 165.75 40.9 0.7 30.0 13here were significant differences in outcome between
EOS and the MIX samples. A significantly greater
ortion of the MIX samples experienced a “good” or
derate” outcome compared to the pure EOS
ples; however, the eff
the three studies with
enced high numbers
ging from 60.5% to 79%
le 5 Outcome by duration of follow-up based on 21 studies (N= 716)
ome variable Percentages of subjects by duration of foll
<10 yrs >10 yrs
Mean SD Median Mean Rank Mean SD Median Mean
N=187 N=235
19.2 5.9 19.8 269.28 12.4 7.6 12.0 165.52
erate 29.4 14.8 38.2 243.08 20.6 13.3 23.7 186.37
51.4 15.8 42.0 150.18 67.0 18.4 60.5 260.30
N=80 N=214
16.4 11.6 16.0 120.69 20.8 7.7 21.0 157.51
erate 37.5 11.7 37.0 180.86 32.1 13.0 28.0 135.03
46.1 23.5 47.0 126.55 47.1 15.3 51.0 155.33Rank U z p rho
7 16486 −4.60 <.001 0.22
5 20309 −1.52 n.s. 0.07, the percentage of patients with a
aller in the MIX samples than in
ffect sizes were moderate.
s in the samples
udies ranged between a minimum
m of 59%. This distribution was
edian, and studies were classified
%) or a low (<28%) dropout rate.
ition on the three outcome para-
Mann Whitney tests and showed
erences in the “moderate” and
s but not in the “good” outcome
The rate of “moderate” outcomes
er in the low attrition samples
attrition samples, whereas the op-
the “poor” outcome group with a
tcomes in the high attrition sam-
2 7383 −4.54 <.001 0.22
4 8606 −2.82 .005 0.14
2 8287 −3.27 .001 0.16ect sizes were small. In contrast,
a dropout rate of 0% all experi-
of “poor” outcome [6,23,55], ran-
.
ow-up
Analysis
Rank U z p rho
11167.5 −8.74 <.001 0.43
16067.0 −4.78 <.001 0.23
10505.5 −9.28 <.001 0.45
6415.0 −3.35 .001 0.20
5891.0 −4.16 <.001 0.24
6884.0 −2.61 .009 0.15
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http:cts of the measures of functioning
rder to assess the effect of measures of functioning,
ies based on GFS were compared to those using SSF
sures. As shown in Table 4, there were highly signifi-
t differences in the outcomes based on these two
sures of functioning in the “good” and “poor” out-
e groups of the EOS samples and the MIX samples.
he latter sample, the outcome also differed signifi-
tly for the “moderate” outcome group. In the EOS
ples, there were lower rates of “good” and “poor”
omes in studies based on GFS compared to SSF out-
es. This was also true for the “moderate” outcome
ps of the MIX samples. The effect sizes were small
all comparisons. In the 5 studies reporting a mean
in EOS patients at follow up based on a total of 199
ents [5,39,50,51,53], the grand mean weighted for
ple sizes of these studies was 47.0.
cts of duration of follow-up
ings that deal with the effect of duration of follow-
re presented in Table 5. In the EOS samples, the ef-
was highly significant for all three outcome groups.
reover, there was a moderate effect size indicating
follow-up longer than 10 years was associated with
maller proportion of patients with a “good” and
however, the effect
the rate of both “g
creasing with longe
of “moderate” outco
Sex effects
Direct calculations c
studies reporting sep
with MIX and 1 w
highly significant dif
erate,” and “poor” o
erally less favoura
frequently than fem
ate” outcome and m
outcome. The effect
To further investi
ple, we compared 6
ies with >50% ma
Differences were si
various levels of out
both EOS and MI
males generally exp
The proportion of “
lower in studies bas
the proportion was
le 6 Outcome by sex based on 5 studies (N=190)
ome variable Percentages of subjects by se
Males Females
Mean SD Median Mean Rank Mean SD Median M
N=92 N=98
17.6 10.6 24.0 82.41 23.2 11.7 30.4 10
erate 23.2 19.3 25.0 68.80 37.3 37.3 46.0 12
59.2 23.2 74.0 107.78 39.5 39.5 36.0 83
//www.biomedcentral.com/1471-244X/12/150derate” outcome and a larger proportion of patients
a “poor” outcome. In the MIX samples, differences
“good” and “moderate” outcomes were highly signifi-
t, and differences were significant for poor outcomes;
Effects of time period o
The data-set allowed a
of studies, namely, th
le 7 Outcome by sex proportions based on 20 studies (N= 707)
come variable Percentages of subjects
<50% males >50% males
Mean SD Median Mean Rank Mean SD Median Mean
N=97 N=316
19.4 5.3 15.8 262.34 13.9 7.9 13.0 190.0
erate 29.9 12.9 25.0 238.20 23.6 14.4 17.0 197.4
50.7 11.0 50.0 175.80 62.5 19.9 62.3 216.5
N=157 N=137
25.0 4.3 27.0 188.68 13.3 9.2 16.0 100.3
erate 36.1 13.1 44.0 160.27 30.7 12.1 28.0 132.8
38.9 10.7 36.0 119.96 56.0 19.9 51.0 179.0es were small. In these samples,
d” and “poor” outcomes was in-
llow-up periods, whereas the rate
was declining.
ld only be made on the basis of five
ate results for males and females (4
EOS patients). As Table 6 shows,
ences were found for “good,” “mod-
ome. These results indicate a gen-
outcome for males who less
s experienced a “good” or “moder-
e frequently experienced a “poor”
es were small to moderate.
e the effect of sex in a larger sam-
dies with <50% males to 14 stud-
findings are shown in Table 7.
ficant to highly significant on the
e. There is a clear indication that
studies containing a majority of
enced a less favourable outcome.
od” and “moderate” outcomes was
on a male predominance, whereas
her in the “poor” outcome groups.
Analysis
Rank U z p rho
3304.0 −3.22 <.001 0.23
2052.0 −6.56 <.001 0.48
3378. −3.03 .002 0.22f diagnosis
dichotomization into two groups
ose including patients diagnosed
Analysis
Rank U z p rho
1 9958 −5.26 <.001 0.26
2 12300 −2.97 .003 0.15
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http:re and after 1970 and those where all patients in the
ple were diagnosed in 1970 or later. Table 8 provides
mparison of the outcome of these two groups. In
EOS samples, there is a highly significant decline of
d” outcomes in all patients diagnosed in or after
0; however, the effect is only small. In contrast, there
large effects indicating that the proportion of “mod-
e” outcomes increased significantly, and the propor-
of “poor” outcomes decreased significantly over
. Taking all three levels into account, the overall
ome improved significantly over time.
here was only one MIX study containing patients
nosed before 1970. On the other hand, there were
r moderate time period effects indicating highly sig-
ant improvements with increasing proportions of
d” and “moderate” outcomes and decreasing pro-
ions of “poor” outcomes.
cussion
s is the first systematic review on the outcome of
that is covering all suitable studies published in the
lish-language literature since 1980. The analyses
e based on statistical tests measuring both the gen-
outcome and the effects of clearly defined predic-
. The review focuses on general trends; one has to
sider that the studies report rather diverse findings,
gh in part, this diversity may be explained by the
ounced heterogeneity of the schizophrenia syn-
e itself [61,62]. Furthermore, the distributions of
main outcome variables of “good,” “moderate,” and
r” differ depending on the measurements and defi-
ns used in the various studies.
he main findings are the following: (a) the outcome
EOS is relatively poor and less favourable than in
the fact that in EO
tioning are associat
comes than specifi
in the MIX sampl
are associated with
(d) in EOS, the effec
favourable outcome
up, whereas in MI
associated with mo
“poor” outcomes; (e
samples is less favo
is better in patients
cent decades. In the
findings will be put
General outcome
In the current revie
patients experience
enced a “moderate”
“poor” outcome. C
EOS is still a ment
prognosis; this conc
reviews [5,7,12,21,3
previous reviews w
and they did not e
authors do in the cu
Furthermore, from
dent that studies o
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EOS and patients w
Unfortunately, sepa
various psychotic
addition, difference
the two samples m
mensen et al. BMC Psychiatry 2012, 12:150
//www.biomedcentral.com/1471-244X/12/150samples; (b) samples with high dropout rates report
“moderate” and more “poor” outcomes, even though
effect sizes are small; (c) the effect sizes of measures
unctioning are also small, which can be attributed to
the different outcome
some indirect evidence
e., schizoaffective disor
disorders with psycho
le 8 Outcome by time period of diagnosis (N=705)
ome variable Percentages of subjects by period of diag
<1970+ ≥1970
Mean SD Median Mean Rank Mean SD Median Mean Ra
N=216 N=195
16.2 7.6 15.8 228.03 15.8 7.1 19.8 181.60
erate 17.2 7.3 17.0 137.25 24.9 15.8 38.2 282.15
66.6 12.9 62.3 274.75 59.3 20.3 44.0 129.85
N=28 N=266
3.6 0.0 3.6 38.50 19.6 7.9 21.0 158.97
erate 17.9 0.0 17.9 14.50 33.6 12.5 37.0 161.50
78.5 0.0 78.5 256.50 46.8 15.3 47.0 133.03
: <1970+: studies including patients diagnosed before and after 1970.
0: Studies containing patients diagnosed in 1970 and later.samples global measures of func-
with less “good” and “poor” out-
easures of functioning; however,
specific measures of functioning
tter outcomes on all three levels;
f duration of follow-up shows less
fter more than 10 years of follow-
samples, the longer follow-up is
“good,” less “moderate,” and more
e outcome in both EOS and MIX
ble in males; and (f ) the outcome
o had been diagnosed in more re-
bsequent paragraphs, these major
o perspective.
we discovered that 15.4% of EOS
a “good” outcome, 24.5% experi-
utcome, and 60.1% experienced a
rly, these findings indicate that
illness with a rather unfavourable
ion is in accordance with previous
3,64]. On the other hand, these
based on non-aggregated data,
loy rigorous data analyses as the
nt review.
he current analyses, it became evi-
atients with EOS show a worse
s containing both patients with
other psychotic disorders (MIX).
e analyses of the outcome of the
sorders were not feasible. In
time points of measurement in
have been operant. Nevertheless,
Page 10 of 16in the two groups may serve as
that other psychotic disorders, i.
ders, schizophreniform or bipolar
tic features, take a less serious
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nk U z p rho
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http:rse in terms of chronicity and functioning because all
lyses based on the mixed psychotic samples showed
ss severe outcome than the pure EOS samples. This
ing is in accordance with similar studies in adults
5].
hen considering the impact of dropout rates, the
eral findings on outcome may be only slightly differ-
than one would expect without any attrition in the
ples. In samples with high attrition rates, patients
a “moderate” course of the disorder were less likely
e followed up, and those with a “poor” outcome
e more likely to show up at follow-up assessments at
various sites, whereas there was no attrition effect
he rate of “good” outcomes. In contrast, it is unclear
ther the rate of “poor” outcomes would be different.
the one hand, our analyses showed that the rate of
r” outcomes declined significantly with low attrition
s. On the other hand, three studies without any attri-
showed an increased rate of “poor” outcomes. How-
, one has to keep in mind that the effect sizes for
ition were only small. High dropout rates are very
mon in psychiatric services with estimated rates ran-
from 20 to 60% [66], which proves to be in line
the findings in the current review with dropout
s between 0 and 59% and a median of 29%.
act of age at onset
contrast to EOS, the outcome in studies of adult
ents is generally more favourable [5]. Hegarty et al.
reviewed 320 adult studies from 1895 to 1992 (more
50,000 patients in total) and found that approxi-
ely 40% improved considerably during follow-up.
& Harrow [2] reviewed nine North American stud-
and the WHO-coordinated International Study of
izophrenia (ISoS), all with a follow-up period of
years or longer, and concluded that, although adult
ents with schizophrenia as a group have a worse out-
e than other psychiatric patients, only a few patients
w a progressive deteriorating course; depending on
strictness of the criteria used for diagnosis, 21-57%
erience a “good” outcome. The ISoS compared long-
follow-up studies (10–15 years) from 14 culturally
rsely treated incidence cohorts and four prevalence
orts, totaling 1633 subjects, and found that approxi-
ely 50% experience a “good” outcome [65].
recent international study that examined outcome
r three years of follow-up in adult outpatient schizo-
enia (N = 11.078 from 37 countries) found that 66%
eved clinical remission measured with the CGI,
reas only 25.4% achieved functional remission
ned as good social functioning for 6 months in terms
occupational/vocational status, independent living
active social interactions [68]. There were large re-
al differences in the study. Patients in Europe were
less likely to achiev
better in regards t
outcome both in th
otic group in the
schizophrenia and
and adolescence on
AOS. In compariso
childhood or adoles
particularly poor co
with eating disorder
lar types of analyses
This conclusion is
hort study from Is
study found that ea
the severity of the c
have some prognos
might have a detrim
impact at very cruc
biological maturati
which prove to have
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for a comparison of
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The impact of the m
The current study
the impact of speci
prisingly, the adven
since the seventies
the outcome of EO
ued with an older tr
tioning outcomes.
different traditions
studies, there were
that studies based
slightly lower rates
and no differentiati
studies based on SS
overall pattern is cl
these two types of
effects were also sm
general pattern of
GFS rather than o
mensen et al. BMC Psychiatry 2012, 12:150
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unctional remission. The general
EOS group and the mixed psych-
rrent review clearly shows that
ychosis originating in childhood
erage follows a worse course than
to other disorders originating in
ce, EOS stands out by way of its
e. For instance, the outcome seen
s much better as is shown by simi-
the senior author [69,70].
so supported by a recent large co-
l with 12.071 participants. This
r onset corresponds linearly with
rse of the disorder and appears to
impact [71]. Young age at onset
tal effect on outcome because of
times of development and neuro-
in childhood and adolescence,
ore lasting effects in terms of both
cial impairments [1,32,35,72].
, there are only a small number of
on VEOS patients only, with an
females, whereas there are more
range of age at onset within the
. Furthermore, there is not a sin-
ively on patients with adolescent
hus, there are no real solid data
e outcome of VEOS. Clearly, more
be needed. Given the low preva-
only collaborative studies across
ive at sample sizes needed for a
e effects of age, sex, clinical fea-
cts on the outcome of VEOS.
sures of functioning
he first to make use of analyzing
measures of functioning. Not sur-
f global measures of functioning
o had an effect on the studies of
In contrast, a few studies contin-
ition to define study-specific func-
us, a comparison of these two
came possible. In the pure EOS
tively small effect sizes, indicating
the more recent GFS arrived at
both “good” and “poor” outcomes
in the “moderate” outcomes than
utcomes. Accordingly, in EOS the
ly not more favourable for one of
tcome. In the MIX studies, the
l though more clearly showing a
s favourable outcomes based on
SSF assessments. Thus, the two
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http:lyses point to different findings in the two types of
ies. In other words, the heterogeneity of the MIX
ples favour the SFS outcomes in which the measure-
t might have tipped closer to the differences in the
nostic composition of the samples.
owever, this interpretation is only an assumption that
ds further examination. Particularly, both the validity
the reliability of these measures need to be studied
reater detail. So far, this has been tested only in parts
some of the GFS measures in general child and ado-
ent psychiatry patients [73] but not specifically in
ents suffering from schizophrenia. In particular, the
F confounds symptoms and functioning with lower
gs driven by symptoms, so someone who is symp-
atic but functional will receive a misleadingly low
g.
impact of intervention
eneral, there is very little information on the impact
tervention on the outcome in EOS, even though all
ent samples were seen clinically and received treat-
t. With the exception of a single study [72], all stud-
rovided treatment as usual. In a recent intervention
y with follow-up based on the Australian Early
hosis Prevention and Intervention Centre (EPPIC)
y, the authors found an increase in GAF score with
ean GAF score of 64 at follow-up [42]. By compari-
, Oie et al. [74] found a mean GAS score of 47.7 in
r EOS group containing 15 patients assessed when
were clinically stable on antipsychotic medication
followed up for 13 years. Moreover, Kao et al. [75]
d a mean GAF score of 47 in 19 EOS patients after
ar follow-up, and Gochman et al. [76] found a mean
S score of 43.6 after at least 8 years of follow-up.
he single intervention study included in the current
ew, the mean GAF score was 35 in the interven-
group and 24 in the control group [55]. Only
da et al. [53] found a mean CGAS score of 62.1,
ch is quite comparable to the finding of the EPPIC
y [42].
evertheless, in the latter study [42], the attrition rate
large (22/63) in the total EOS group and well
lained only in a single person who committed sui-
. It is unclear whether the 21 other patients that
e not followed-up represent a subgroup with less
urable outcome because the authors did not provide
orough attrition analysis. Thus, the claim of the
ors that their outcome findings are superior to pre-
s outcomes is not yet substantiated.
impact of duration of follow-up
current analyses revealed, with small to moderate ef-
sizes, that across the three levels, the outcome dete-
ated with longer follow-up periods (>10 years) in the
EOS samples, but t
in the MIX sample
comes increasing at
with longer follow-
point to the already
psychoses, apart fr
present findings nee
cause the two follow
rather broad and re
ing a more fine-gra
lysis was based on a
longitudinal studies
come studies of the
samples that were a
were described in
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an increase in the
the first follow-up a
11 years (19 to 31
comes declined (74
portion of “moder
findings are in cont
view. Lay et al. [41
that had been previo
approximately one t
between the two ass
not the slight shift
(from 32 to 36%) is
dinal studies made
any significant chan
time.
The impact of sex
The current review
carries a less favou
MIX samples. Neve
section, there were
proper analysis of
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ify outcome by sex
analyses had to be p
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favoured females in
The supplementary
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more than half of th
The findings were i
cating that male sex
When looking at
current review, one
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differences [5,8]. On
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ith both “good” and “poor” out-
e expense of “moderate” outcomes
periods. These differences again
oted different course of the other
schizophrenia. Nevertheless, the
to be interpreted with caution be-
p periods of ≤10 and >10 years are
t limitations of the data not allow-
d analysis. Furthermore, the ana-
ries of cross-sectional rather than
nfortunately, among the 21 out-
resent analysis, there are only six
ssed repeatedly for follow-up and
rticles [8,11,29,35,41,53,54,59,60].
nd Müller-Thomsen [11] showed
portion of “good” outcome from
years to the second follow-up at
whereas the rate of “poor” out-
59%) with a rather constant pro-
” outcomes (7 to 10%). These
t to the findings of the current re-
studied a mixed psychotic group
ly followed-up [35]. Unfortunately,
d of the group had dropped out in
ments, so it is unclear whether or
m “moderate” to “poor” outcome
alid finding. None of these longitu-
e of inferential statistical tests of
of the course of the disorder over
pports the notion that male sex
le prognosis in EOS but also in
eless, as described in the methods
found limitations in the data for a
effects. With a few exceptions
t majority of studies did not strat-
us, two rather restricted types of
ormed. The direct comparisons of
able for direct comparisons clearly
rms of having a better outcome.
alysis based on a larger sample
es of samples with either less or
amples being comprised of males.
ine with the previous results indi-
a negative prognostic factor.
various studies considered in the
ay see that some studies reported
outcome for males [1,5,6,8,11,15],
e provided statistically significant
study found a specific “poor” out-
ch proved to be not statistically
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http:ificant [49]. In contrast, most of the 20 studies either
rted no prognostic impact of sex [39,40] or did not
ify or mention sex in relation to outcome measures
23,29,32,38,41,51,53,54]. One study noted that the risk
uicide was increased about 30 times in males [50].
the 21 studies listing the distribution of sex, the
age proportion of males was only 55%, a surprising
overy given that schizophrenia usually has an earlier
et among males than among females [17] and that
onset after age 45 is more common among females
. Especially with regard to VEOS onset, the literature
ts to a male predominance [12] with a ratio of ap-
imately 2–2.5:1 [17,24,64]; however, in the two stud-
of VEOS, female sex was dominant in both series of
ents [23,29]. In conclusion, there is some indication
potential sex bias in the outcome studies in terms of
taining more females than expected. Potential expla-
ons include a higher dropout rate of males from out-
e assessments due to less compliance and/or a
er mortality rate.
impact of time period of diagnosis
time span of the original diagnosis of the patients
ed enormously between 1920 and 2010. During this
od, major changes in the understanding of schizo-
enia including the nosological classification, assess-
t, and intervention took place. Thus, our analysis
potential time period effects into account. The
-set was dichotomized into studies containing
ents diagnosed before or after 1970 and patients all
nosed in 1970 or later. This grouping was not ideal
use it was still based on considerable heterogeneity
erms of the time when the patients were diagnosed.
ertheless, it represented a feasible and pragmatic ap-
ch and reflected the fact that some major changes
he classification of schizophrenia both in the ICD
the DSM took place in the seventies.
he findings indicated that the overall outcome in
and even more clearly in MIX samples improved
time; thus, one may argue that the progress in
tment and rehabilitation of schizophrenia might have
a beneficial effect for those who were born and diag-
ed later. In summary, one may also conclude that the
all relatively poor long-term outcome of EOS is, in
, due to the inclusion of studies containing patients
had been diagnosed many decades ago.
itations
t, we decided to include only studies published after
0, assuming that these studies would reflect a rather
mon international frame of understanding of the
ology of schizophrenia and psychoses. Even with this
riction, though, there was a large time span over
ch patients had been diagnosed. Even more
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and of follow-up as
patients with a rap
have been included
thermore, it is not
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In the current re
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tions. Even among t
fully congruent set
was not only plaus
the various GFS m
compromise consid
of “good,” “moderat
Some of the limit
stated by Jobe & H
[77], are also releva
parability of follow-
ing criteria for diag
selection (i.e., bias
indexing), varying d
the American and
approaches, and pr
leading to different
thermore, many stu
for diagnosis and
patients due to su
outs; however, one
outcome should be
as suggested by Jarb
Furthermore, the
rates in EOS and V
studies that should
EOS and VEOS are
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e of the first clinical presentation
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the beginning of the studies. Fur-
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in the outcome literature of vari-
While the three authors of the
excellent convergence in the out-
rious studies regarding this classi-
e that the cut-offs of these three
batable. Nevertheless, our cut-offs
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ause they are clearly demarcating
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sed slightly different definitions.
sed a lower cut-off of >60 rather
ition of “good” outcomes, whereas
requested a lower cut-off of <40
hus, these differences imply a less
outcome, so our findings might
er if we had accepted these defini-
se five studies, though, there is no
definitions. Thus, our procedure
in terms of the construction of
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g the heterogeneity of definitions
and “poor” outcomes.
ns in reviews of schizophrenia, as
row [2] and Castle and Morgan
for the current analyses. The com-
studies is compromised by differ-
sis and outcome variables, sample
etween inpatient and outpatient
ation of follow-up, differences in
uropean tradition of diagnostic
pective and retrospective designs
eciseness of data acquisition. Fur-
s have used different assessments
tcome. Various studies have lost
e, which were counted as drop-
uld argue that suicide in terms of
ted in the “poor” outcome group,
[50].
k of any clear data on mortality
OS is a shortcoming of outcome
addressed in future studies. Since
ry rare, patients often come from
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http:rge geographic area to the specialist research units;
, some patients travel far to be part of the study.
s might be a bias in terms of only the most affected
viduals will travel this far to be part of a study, which
indicates that the patients who have the best out-
e might drop out.
nally, no firm conclusions can be made thus far as to
effects of interventions, and it is unclear whether the
e variation is due to different interventions, varying
ical manifestations, or an interaction of both. As
the study of other disorders, research on the effects
intervention on course and outcome is most
lected. Further studies are clearly needed.
clusions
s exhaustive analysis of the available evidence on the
ome of EOS and VEOS points to the still rather
r prognosis of early manifestations of schizophrenia.
outcome of schizophrenia is worse than for other
hotic disorders, which applies to both adult and
y onset schizophrenia. In both AOS and in EOS,
gh, there are many individual differences and so the
rse and outcome of schizophrenia is rather heteroge-
us. Further insight into the long-term course of EOS
ht result from refinements in the design of future
ies. Most particularly, the course of the individual
ent will ultimately profit from a better understanding
the causes and refined treatment of this serious
rder.
ture studies on the long-term outcome of EOS
ht benefit from the following: (a) commonly used
nostic criteria and standardized assessments; (b)
iled description of sample characteristics; (c) low at-
on rates of the sample; (d) repeated and long-term
w-up assessments with standardized instruments
ring clinical symptoms and functioning; (e) detailed
rmation on type and duration of interventions in-
ing their effects on outcome; and (f ) the use of large
egated samples. These samples might be identified
ational registers so that a potential sample bias
ed by local hospital recruitment might be avoided.
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Adult onset schizophrenia; MIX: Studies including both EOS and other
otic disorders; GFS: General functioning scale; SSF: Study-specific
ioning; GAF: Global assessment of functioning; CGAS: Children’s global
sment scale; GAS: Global assessment scale.
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